BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC, Mendoza TR, Hay J, Atkinson TM, Abernethy AP, Bruner DW, Cleeland CS, Sloan JA, Chilukuri R, Baumgartner P, Denicoff A, St Germain D, O'Mara AM, Chen A, Kelaghan J, Bennett AV, Sit L, Rogak L, Barz A, Paul DB, Schrag D. Development of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst. 2014;106. [PMID: 25265940 DOI: 10.1093/jnci/dju244] [Cited by in Crossref: 364] [Cited by in F6Publishing: 270] [Article Influence: 52.0] [Reference Citation Analysis]
Number Citing Articles
1 Williams LA, Garcia-Gonzalez A, Mendoza TR, Haq S, Cleeland CS. Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). Support Care Cancer 2019;27:1021-8. [PMID: 30094731 DOI: 10.1007/s00520-018-4391-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Reeve BB, McFatrich M, Lin L, Lucas NR, Mack JW, Jacobs SS, Withycombe JS, Baker JN, Freyer DR, Hinds PS. Validation of the caregiver Pediatric Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events measure. Cancer 2021;127:1483-94. [PMID: 33332590 DOI: 10.1002/cncr.33389] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Valade S, Joly BS, Veyradier A, Fadlallah J, Zafrani L, Lemiale V, Launois A, Stepanian A, Galicier L, Fieschi C, Mirouse A, Tudesq JJ, Lepretre AC, Azoulay E, Darmon M, Mariotte E. Coagulation disorders in patients with severe hemophagocytic lymphohistiocytosis. PLoS One 2021;16:e0251216. [PMID: 34343182 DOI: 10.1371/journal.pone.0251216] [Reference Citation Analysis]
4 Allen EN, Chandler CI, Mandimika N, Leisegang C, Barnes K. Eliciting adverse effects data from participants in clinical trials. Cochrane Database Syst Rev 2018;1:MR000039. [PMID: 29372930 DOI: 10.1002/14651858.MR000039.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
5 Warsame R, D'Souza A. Patient Reported Outcomes Have Arrived: A Practical Overview for Clinicians in Using Patient Reported Outcomes in Oncology. Mayo Clin Proc 2019;94:2291-301. [PMID: 31563425 DOI: 10.1016/j.mayocp.2019.04.005] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
6 Regnault A, Pompilus F, Ciesluk A, Mazerolle F, Bejar R, Fram RJ, Faller DV, Marquis P, Bell JA. Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30. J Patient Rep Outcomes 2021;5:60. [PMID: 34283303 DOI: 10.1186/s41687-021-00334-w] [Reference Citation Analysis]
7 Pergolotti M, Lyons KD, Williams GR. Moving beyond symptom management towards cancer rehabilitation for older adults: Answering the 5W's. Journal of Geriatric Oncology 2018;9:543-9. [DOI: 10.1016/j.jgo.2017.11.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
8 Doussot A, Gluskin J, Groot-Koerkamp B, Allen PJ, De Matteo RP, Shia J, Kingham TP, Jarnagin WR, Gerst SR, D'Angelica MI. The accuracy of pre-operative imaging in the management of hepatic cysts. HPB (Oxford) 2015;17:889-95. [PMID: 26227923 DOI: 10.1111/hpb.12443] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
9 Kurosawa S, Yamaguchi T, Mori A, Tsukagoshi M, Okuda I, Kayama M, Fuji S, Yamashita T, Ogawa C, Ito A, Tanaka T, Inamoto Y, Kim SW, Fukuda T. Prognostic Impact of Pretransplantation Quality of Life and Its Post-Transplantation Longitudinal Change after Allogeneic Hematopoietic Cell Transplantation: A Prospective Study That Administered the Short-Form Health Survey (SF-12) and EuroQol 5. Transplant Cell Ther 2021:S2666-6367(21)01108-8. [PMID: 34371214 DOI: 10.1016/j.jtct.2021.07.026] [Reference Citation Analysis]
10 Petersen C. Patient-generated health data: a pathway to enhanced long-term cancer survivorship. J Am Med Inform Assoc 2016;23:456-61. [PMID: 26714765 DOI: 10.1093/jamia/ocv184] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
11 Kestler AMR, Kühlwein SD, Kraus JM, Schwab JD, Szekely R, Thiam P, Hühne R, Jahn N, Fürstberger A, Ikonomi N, Balig J, Schuler R, Kuhn P, Steger F, Seufferlein T, Kestler HA. Digitalization of adverse event management in oncology to improve treatment outcome-A prospective study protocol. PLoS One 2021;16:e0252493. [PMID: 34086740 DOI: 10.1371/journal.pone.0252493] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Basch E, Dueck AC, Rogak LJ, Minasian LM, Kelly WK, O'Mara AM, Denicoff AM, Seisler D, Atherton PJ, Paskett E, Carey L, Dickler M, Heist RS, Himelstein A, Rugo HS, Sikov WM, Socinski MA, Venook AP, Weckstein DJ, Lake DE, Biggs DD, Freedman RA, Kuzma C, Kirshner JJ, Schrag D. Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 2017;3:1043-50. [PMID: 28208174 DOI: 10.1001/jamaoncol.2016.6749] [Cited by in Crossref: 62] [Cited by in F6Publishing: 40] [Article Influence: 15.5] [Reference Citation Analysis]
13 Trask PC, Dueck AC, Piault E, Campbell A. Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events: Methods for item selection in industry-sponsored oncology clinical trials. Clin Trials 2018;15:616-23. [PMID: 30230365 DOI: 10.1177/1740774518799985] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
14 Doussot A, Nardin C, Takaki H, Litchman TD, D'Angelica MI, Jarnagin WR, Postow MA, Erinjeri JP, Kingham TP. Liver resection and ablation for metastatic melanoma: A single center experience. J Surg Oncol 2015;111:962-8. [PMID: 26073980 DOI: 10.1002/jso.23929] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
15 Arnaboldi P, Oliveri S, Vergani L, Marton G, Guiddi P, Busacchio D, Didier F, Pravettoni G. The clinical-care focused psychological interview (CLiC): a structured tool for the assessment of cancer patients' needs. Ecancermedicalscience 2020;14:1000. [PMID: 32153655 DOI: 10.3332/ecancer.2020.1000] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
16 Chera BS, Fried D, Price A, Amdur RJ, Mendenhall W, Lu C, Das S, Sheets N, Marks L, Mavroidis P. Dosimetric Predictors of Patient-Reported Xerostomia and Dysphagia With Deintensified Chemoradiation Therapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma. Int J Radiat Oncol Biol Phys 2017;98:1022-7. [PMID: 28721884 DOI: 10.1016/j.ijrobp.2017.03.034] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Schuurhuizen C, Braamse A, Konings I, Sprangers M, Ket J, Dekker J, Verheul H. Does severe toxicity affect global quality of life in patients with metastatic colorectal cancer during palliative systemic treatment? A systematic review. Annals of Oncology 2017;28:478-86. [DOI: 10.1093/annonc/mdw617] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
18 Grašič Kuhar C, Gortnar Cepeda T, Kovač T, Kukar M, Ružić Gorenjec N. Mobile App for Symptom Management and Associated Quality of Life During Systemic Treatment in Early Stage Breast Cancer: Nonrandomized Controlled Prospective Cohort Study. JMIR Mhealth Uhealth 2020;8:e17408. [PMID: 32427567 DOI: 10.2196/17408] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Shirato H, Le QT, Kobashi K, Prayongrat A, Takao S, Shimizu S, Giaccia A, Xing L, Umegaki K. Selection of external beam radiotherapy approaches for precise and accurate cancer treatment. J Radiat Res 2018;59:i2-i10. [PMID: 29373709 DOI: 10.1093/jrr/rrx092] [Cited by in Crossref: 15] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
20 Yasueda A, Mizushima T, Nezu R, Sumi R, Tanaka M, Nishimura J, Kai Y, Hirota M, Osawa H, Nakajima K, Mori M, Ito T. The effect of Clostridium butyricum MIYAIRI on the prevention of pouchitis and alteration of the microbiota profile in patients with ulcerative colitis. Surg Today 2016;46:939-49. [DOI: 10.1007/s00595-015-1261-9] [Cited by in Crossref: 58] [Cited by in F6Publishing: 39] [Article Influence: 9.7] [Reference Citation Analysis]
21 Falchook AD, Green R, Knowles ME, Amdur RJ, Mendenhall W, Hayes DN, Grilley-Olson JE, Weiss J, Reeve BB, Mitchell SA, Basch EM, Chera BS. Comparison of Patient- and Practitioner-Reported Toxic Effects Associated With Chemoradiotherapy for Head and Neck Cancer. JAMA Otolaryngol Head Neck Surg 2016;142:517-23. [PMID: 27149571 DOI: 10.1001/jamaoto.2016.0656] [Cited by in Crossref: 48] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
22 Atkinson TM, Rogak LJ, Heon N, Ryan SJ, Shaw M, Stark LP, Bennett AV, Basch E, Li Y. Exploring differences in adverse symptom event grading thresholds between clinicians and patients in the clinical trial setting. J Cancer Res Clin Oncol 2017;143:735-43. [PMID: 28093637 DOI: 10.1007/s00432-016-2335-9] [Cited by in Crossref: 22] [Cited by in F6Publishing: 14] [Article Influence: 5.5] [Reference Citation Analysis]
23 Fares CM, Williamson TJ, Theisen MK, Cummings A, Bornazyan K, Carroll J, Spiegel ML, Stanton AL, Garon EB. Low Concordance of Patient-Reported Outcomes With Clinical and Clinical Trial Documentation. JCO Clin Cancer Inform 2018;2:1-12. [PMID: 30652613 DOI: 10.1200/CCI.18.00059] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
24 Rothrock NE, Cook KF, O'Connor M, Cella D, Smith AW, Yount SE. Establishing clinically-relevant terms and severity thresholds for Patient-Reported Outcomes Measurement Information System® (PROMIS®) measures of physical function, cognitive function, and sleep disturbance in people with cancer using standard setting. Qual Life Res 2019;28:3355-62. [PMID: 31410640 DOI: 10.1007/s11136-019-02261-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
25 Alberti P. Platinum-drugs induced peripheral neurotoxicity: clinical course and preclinical evidence. Expert Opinion on Drug Metabolism & Toxicology 2019;15:487-97. [DOI: 10.1080/17425255.2019.1622679] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
26 Hay JL, Atkinson TM, Reeve BB, Mitchell SA, Mendoza TR, Willis G, Minasian LM, Clauser SB, Denicoff A, O'Mara A, Chen A, Bennett AV, Paul DB, Gagne J, Rogak L, Sit L, Viswanath V, Schrag D, Basch E; NCI PRO-CTCAE Study Group. Cognitive interviewing of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Qual Life Res 2014;23:257-69. [PMID: 23868457 DOI: 10.1007/s11136-013-0470-1] [Cited by in Crossref: 76] [Cited by in F6Publishing: 62] [Article Influence: 9.5] [Reference Citation Analysis]
27 Timmers L, Boons CC, Mangnus D, Van de Ven PM, Van den Berg PH, Beeker A, Swart EL, Honeywell RJ, Peters GJ, Boven E, Hugtenburg JG. Adherence and Patients' Experiences with the Use of Capecitabine in Daily Practice. Front Pharmacol 2016;7:310. [PMID: 27708578 DOI: 10.3389/fphar.2016.00310] [Cited by in Crossref: 11] [Cited by in F6Publishing: 4] [Article Influence: 2.2] [Reference Citation Analysis]
28 Ganz PA, Dougherty PM. Painful Hands and Feet After Cancer Treatment: Inflammation Affecting the Mind-Body Connection. J Clin Oncol 2016;34:649-52. [PMID: 26700128 DOI: 10.1200/JCO.2015.64.7479] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
29 Speck RM, Lenderking WR, Shaw JW. Integrating the patient voice with clinician reports to identify a hepatocellular carcinoma-specific subset of treatment-related symptomatic adverse events. J Patient Rep Outcomes 2017;2:35. [PMID: 30175317 DOI: 10.1186/s41687-018-0063-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Deshields TL, Penalba V, Liu J, Avery J. Comparing the symptom experience of cancer patients and non-cancer patients. Support Care Cancer 2017;25:1103-9. [PMID: 27966024 DOI: 10.1007/s00520-016-3498-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
31 Kober KM, Roy R, Dhruva A, Conley YP, Chan RJ, Cooper B, Olshen A, Miaskowski C. Prediction of evening fatigue severity in outpatients receiving chemotherapy: less may be more. Fatigue 2021;9:14-32. [PMID: 34249477 DOI: 10.1080/21641846.2021.1885119] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Voong KR, Han P, Hales R, Hill C, Friedes C, McNutt T, Lee S, Snyder C. Patient-Reported Outcome Measures and Dosimetric Correlates for Early Detection of Acute Radiation Therapy-Related Esophagitis. Pract Radiat Oncol 2021;11:185-92. [PMID: 33137465 DOI: 10.1016/j.prro.2020.10.009] [Reference Citation Analysis]
33 Cao Z, Xiong X, Yang Q. [Establishment of naive Bayes classifier-based risk prediction model for chemotherapyinduced nausea and vomiting]. Nan Fang Yi Ke Da Xue Xue Bao 2021;41:607-12. [PMID: 33963723 DOI: 10.12122/j.issn.1673-4254.2021.04.19] [Reference Citation Analysis]
34 Park R, Shaw JW, Korn A, McAuliffe J. The value of immunotherapy for survivors of stage IV non-small cell lung cancer: patient perspectives on quality of life. J Cancer Surviv 2020;14:363-76. [PMID: 31950409 DOI: 10.1007/s11764-020-00853-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
35 Di Maio M, Basch E, Bryce J, Perrone F. Patient-reported outcomes in the evaluation of toxicity of anticancer treatments. Nat Rev Clin Oncol 2016;13:319-25. [DOI: 10.1038/nrclinonc.2015.222] [Cited by in Crossref: 108] [Cited by in F6Publishing: 80] [Article Influence: 21.6] [Reference Citation Analysis]
36 Gil KM, Pugh SL, Klopp AH, Yeung AR, Wenzel L, Westin SN, Gaffney DK, Small W Jr, Thompson S, Doncals DE, Cantuaria GHC, Yaremko BP, Chang A, Kundapur V, Mohan DS, Haas ML, Kim YB, Ferguson CL, Deshmukh S, Kachnic LA, Bruner DW. Expanded validation of the EPIC bowel and urinary domains for use in women with gynecologic cancer undergoing postoperative radiotherapy. Gynecol Oncol 2019;154:183-8. [PMID: 31104905 DOI: 10.1016/j.ygyno.2019.04.682] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
37 Chung AE, Shoenbill K, Mitchell SA, Dueck AC, Schrag D, Bruner DW, Minasian LM, St Germain D, O'Mara AM, Baumgartner P, Rogak LJ, Abernethy AP, Griffin AC, Basch EM. Patient free text reporting of symptomatic adverse events in cancer clinical research using the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Am Med Inform Assoc 2019;26:276-85. [PMID: 30840079 DOI: 10.1093/jamia/ocy169] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 20.0] [Reference Citation Analysis]
38 Nyrop KA, Deal AM, Reeder-Hayes KE, Shachar SS, Reeve BB, Basch E, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB. Patient-reported and clinician-reported chemotherapy-induced peripheral neuropathy in patients with early breast cancer: Current clinical practice. Cancer 2019;125:2945-54. [PMID: 31090930 DOI: 10.1002/cncr.32175] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 12.0] [Reference Citation Analysis]
39 Kanzawa-Lee GA. Chemotherapy-Induced Peripheral Neuropathy: Nursing Implications. J Infus Nurs 2020;43:155-66. [PMID: 32287170 DOI: 10.1097/NAN.0000000000000368] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
40 Chien TJ, Liu CY, Ko PH, Hsu CH. A Chinese Decoction, Kuan-Sin-Yin, Improves Autonomic Function and Cancer-Related Symptoms of Metastatic Colon Cancer. Integr Cancer Ther 2016;15:113-23. [PMID: 26612784 DOI: 10.1177/1534735415617282] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
41 Coon CD. The Use of Patient-reported Outcomes in Demonstrating Safety and Efficacy in Oncology. Clin Ther 2016;38:756-8. [PMID: 27038639 DOI: 10.1016/j.clinthera.2016.03.015] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
42 Witt JS, Musunuru HB, Bayliss RA, Howard SP. Large volume re-irradiation for recurrent meningioma with pulsed reduced dose rate radiotherapy. J Neurooncol 2019;141:103-9. [PMID: 30392090 DOI: 10.1007/s11060-018-03011-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
43 Bouazza YB, Chiairi I, El Kharbouchi O, De Backer L, Vanhoutte G, Janssens A, Van Meerbeeck JP. Patient-reported outcome measures (PROMs) in the management of lung cancer: A systematic review. Lung Cancer 2017;113:140-51. [DOI: 10.1016/j.lungcan.2017.09.011] [Cited by in Crossref: 37] [Cited by in F6Publishing: 26] [Article Influence: 9.3] [Reference Citation Analysis]
44 Berman AT, Rosenthal SA, Moghanaki D, Woodhouse KD, Movsas B, Vapiwala N. Focusing on the "Person" in Personalized Medicine: The Future of Patient-Centered Care in Radiation Oncology. J Am Coll Radiol 2016;13:1571-8. [PMID: 27888944 DOI: 10.1016/j.jacr.2016.09.012] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
45 Kishan AU, Wang PC, Sharif J, Kupelian PA, Steinberg ML, McCloskey SA. Clinical Indicators of Psychosocial Distress Predict for Acute Radiation-Induced Fatigue in Patients Receiving Adjuvant Radiation Therapy for Breast Cancer: An Analysis of Patient-Reported Outcomes. Int J Radiat Oncol Biol Phys 2016;95:946-55. [PMID: 27105720 DOI: 10.1016/j.ijrobp.2016.01.062] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
46 Phillips JD, Wong SL. Patient-Reported Outcomes in Surgical Oncology: An Overview of Instruments and Scores. Ann Surg Oncol 2020;27:45-53. [PMID: 31463699 DOI: 10.1245/s10434-019-07752-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
47 Gilbert A, Sebag-montefiore D, Davidson S, Velikova G. Use of patient-reported outcomes to measure symptoms and health related quality of life in the clinic. Gynecologic Oncology 2015;136:429-39. [DOI: 10.1016/j.ygyno.2014.11.071] [Cited by in Crossref: 53] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
48 Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, Antonarakis ES, Beer TM, Carducci MA, Chi KN, Corn PG, de Bono JS, Dreicer R, George DJ, Heath EI, Hussain M, Kelly WK, Liu G, Logothetis C, Nanus D, Stein MN, Rathkopf DE, Slovin SF, Ryan CJ, Sartor O, Small EJ, Smith MR, Sternberg CN, Taplin ME, Wilding G, Nelson PS, Schwartz LH, Halabi S, Kantoff PW, Armstrong AJ; Prostate Cancer Clinical Trials Working Group 3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402-1418. [PMID: 26903579 DOI: 10.1200/jco.2015.64.2702] [Cited by in Crossref: 568] [Cited by in F6Publishing: 211] [Article Influence: 113.6] [Reference Citation Analysis]
49 Unger JM, Griffin K, Donaldson GW, Baranowski KM, Good MJ, Reburiano E, Hussain M, Monk PJ, Van Veldhuizen PJ, Carducci MA, Higano CS, Lara PN, Tangen CM, Quinn DI, Wade JL III, Vogelzang NJ, Thompson IM Jr, Moinpour CM. Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421). J Patient Rep Outcomes 2017;2:27. [PMID: 29951640 DOI: 10.1186/s41687-018-0054-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 2.3] [Reference Citation Analysis]
50 Cortes J, Hudgens S, Twelves C, Perez EA, Awada A, Yelle L, McCutcheon S, Kaufman PA, Forsythe A, Velikova G. Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trial. Breast Cancer Res Treat 2015;154:509-20. [PMID: 26567010 DOI: 10.1007/s10549-015-3633-7] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
51 Nakano M, Kuromatsu R, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Kamachi N, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma. ESMO Open 2021;6:100020. [PMID: 33399083 DOI: 10.1016/j.esmoop.2020.100020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Schoen MW, Basch E, Hudson LL, Chung AE, Mendoza TR, Mitchell SA, St Germain D, Baumgartner P, Sit L, Rogak LJ, Shouery M, Shalley E, Reeve BB, Fawzy MR, Bhavsar NA, Cleeland C, Schrag D, Dueck AC, Abernethy AP. Software for Administering the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. JMIR Hum Factors 2018;5:e10070. [PMID: 30012546 DOI: 10.2196/10070] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
53 Beijers AJ, Oerlemans S, Mols F, Eurelings M, Minnema MC, Vreugdenhil A, van de Poll-Franse LV. The magnitude of neurotoxicity in patients with multiple myeloma and the impact of dose modifications: results from the population-based PROFILES registry. Ann Hematol 2017;96:653-63. [PMID: 28116479 DOI: 10.1007/s00277-017-2927-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
54 Knoerl R, Gray E, Stricker C, Mitchell SA, Kippe K, Smith G, Dudley WN, Lavoie Smith EM. Electronic versus paper-pencil methods for assessing chemotherapy-induced peripheral neuropathy. Support Care Cancer 2017;25:3437-46. [PMID: 28577231 DOI: 10.1007/s00520-017-3764-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
55 Garg S, Williams NL, Ip A, Dicker AP. Clinical Integration of Digital Solutions in Health Care: An Overview of the Current Landscape of Digital Technologies in Cancer Care. JCO Clin Cancer Inform 2018;2:1-9. [PMID: 30652580 DOI: 10.1200/CCI.17.00159] [Cited by in Crossref: 39] [Cited by in F6Publishing: 9] [Article Influence: 19.5] [Reference Citation Analysis]
56 Kamgar M, Greenwald MK, Assad H, Hastert TA, McLaughlin EM, Reding KW, Paskett ED, Bea JW, Shadyab AH, Neuhouser ML, Nassir R, Crane TE, Sreeram K, Simon MS. Prevalence and predictors of peripheral neuropathy after breast cancer treatment. Cancer Med 2021. [PMID: 34390205 DOI: 10.1002/cam4.4202] [Reference Citation Analysis]
57 Bandos H, Melnikow J, Rivera DR, Swain SM, Sturtz K, Fehrenbacher L, Wade JL 3rd, Brufsky AM, Julian TB, Margolese RG, McCarron EC, Ganz PA. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst 2018;110. [PMID: 28954297 DOI: 10.1093/jnci/djx162] [Cited by in Crossref: 40] [Cited by in F6Publishing: 29] [Article Influence: 10.0] [Reference Citation Analysis]
58 Sandler KA, Mitchell SA, Basch E, Raldow AC, Steinberg ML, Sharif J, Cook RR, Kupelian PA, McCloskey SA. Content Validity of Anatomic Site-Specific Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Sets for Assessment of Acute Symptomatic Toxicities in Radiation Oncology. Int J Radiat Oncol Biol Phys 2018;102:44-52. [PMID: 30102201 DOI: 10.1016/j.ijrobp.2018.04.048] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 5.3] [Reference Citation Analysis]
59 Addario B, Geissler J, Horn MK, Krebs LU, Maskens D, Oliver K, Plate A, Schwartz E, Willmarth N. Including the patient voice in the development and implementation of patient-reported outcomes in cancer clinical trials. Health Expect 2020;23:41-51. [PMID: 31722131 DOI: 10.1111/hex.12997] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
60 Chang L, Guo R. Comparison of the efficacy among multiple chemotherapeutic interventions combined with radiation therapy for patients with cervix cancer after surgery: A network meta-analysis. Oncotarget 2017;8:49515-33. [PMID: 28472781 DOI: 10.18632/oncotarget.17259] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
61 Glynne-jones R, Adams R, Lopes A, Meadows H. Clinical endpoints in trials of chemoradiation for patients with anal cancer. The Lancet Oncology 2017;18:e218-27. [DOI: 10.1016/s1470-2045(17)30190-0] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 4.3] [Reference Citation Analysis]
62 Pérez-Alfonso KE, Sánchez-Martínez V. Electronic Patient-Reported Outcome Measures Evaluating Cancer Symptoms: A Systematic Review. Semin Oncol Nurs 2021;37:151145. [PMID: 33773879 DOI: 10.1016/j.soncn.2021.151145] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
63 Basch E, Stover AM, Schrag D, Chung A, Jansen J, Henson S, Carr P, Ginos B, Deal A, Spears PA, Jonsson M, Bennett AV, Mody G, Thanarajasingam G, Rogak LJ, Reeve BB, Snyder C, Kottschade LA, Charlot M, Weiss A, Bruner D, Dueck AC. Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial. JCO Clin Cancer Inform 2020;4:947-57. [PMID: 33112661 DOI: 10.1200/CCI.20.00081] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 14.0] [Reference Citation Analysis]
64 Bæksted CW, Nissen A, Knoop AS, Pappot H. Patients' experience of communication and handling of symptomatic adverse events in breast cancer patients receiving adjuvant chemotherapy. Res Involv Engagem 2019;5:36. [PMID: 31832240 DOI: 10.1186/s40900-019-0171-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Drago JZ, Gönen M, Thanarajasingam G, Sacks CA, Morris MJ, Kantoff PW, Stopsack KH. Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. J Natl Cancer Inst 2021;113:553-61. [PMID: 32857839 DOI: 10.1093/jnci/djaa134] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
66 Wilson MK, Mercieca-Bebber R, Friedlander M. A practical guide to understanding, using and including patient reported outcomes in clinical trials in ovarian cancer. J Gynecol Oncol 2018;29:e81. [PMID: 30022641 DOI: 10.3802/jgo.2018.29.e81] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
67 Rydén A, Blackhall F, Kim HR, Pillai RN, Braam L, Martin ML, Walding A. Patient Experience of Symptoms and Side Effects when Treated with Osimertinib for Advanced Non-Small-Cell Lung Cancer: A Qualitative Interview Substudy. Patient 2017;10:593-603. [DOI: 10.1007/s40271-017-0229-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
68 Hagelstein V, Ortland I, Wilmer A, Mitchell SA, Jaehde U. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE™). Ann Oncol 2016;27:2294-9. [PMID: 27681863 DOI: 10.1093/annonc/mdw422] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
69 Jain V, Bahia J, Mohebtash M, Barac A. Cardiovascular Complications Associated With Novel Cancer Immunotherapies. Curr Treat Options Cardiovasc Med 2017;19:36. [PMID: 28401456 DOI: 10.1007/s11936-017-0532-8] [Cited by in Crossref: 49] [Cited by in F6Publishing: 38] [Article Influence: 12.3] [Reference Citation Analysis]
70 Chae YK, Arya A, Iams W, Cruz MR, Chandra S, Choi J, Giles F. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). J Immunother Cancer 2018;6:39. [PMID: 29769148 DOI: 10.1186/s40425-018-0349-3] [Cited by in Crossref: 139] [Cited by in F6Publishing: 123] [Article Influence: 46.3] [Reference Citation Analysis]
71 Raju GK, Gurumurthi K, Domike R. Benefit-Risk Analysis for Decision-Making: An Approach. Clin Pharmacol Ther 2016;100:654-71. [PMID: 27627788 DOI: 10.1002/cpt.507] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
72 Pang X, Huang L, Ma Y, Liu Z, Xie P, Liu H, Wan X, Liu S, Zheng J. Management of Clinically Involved Lateral Lymph Node Metastasis in Locally Advanced Rectal Cancer: A Radiation Dose Escalation Study. Front Oncol 2021;11:674253. [PMID: 34336663 DOI: 10.3389/fonc.2021.674253] [Reference Citation Analysis]
73 Dueck AC, Scher HI, Bennett AV, Mazza GL, Thanarajasingam G, Schwab G, Weitzman AL, Rogak LJ, Basch E. Assessment of Adverse Events From the Patient Perspective in a Phase 3 Metastatic Castration-Resistant Prostate Cancer Clinical Trial. JAMA Oncol 2020;6:e193332. [PMID: 31556911 DOI: 10.1001/jamaoncol.2019.3332] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
74 Reeve BB, McFatrich M, Pinheiro LC, Freyer DR, Basch EM, Baker JN, Withycombe JS, Sung L, Mack JW, Waldron MK, Mowbray C, Palma D, Hinds PS. Cognitive Interview-Based Validation of the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in Adolescents with Cancer. J Pain Symptom Manage 2017;53:759-66. [PMID: 28062347 DOI: 10.1016/j.jpainsymman.2016.11.006] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
75 Martini C, Gamper EM, Wintner L, Nilica B, Sperner-Unterweger B, Holzner B, Virgolini I. Systematic review reveals lack of quality in reporting health-related quality of life in patients with gastroenteropancreatic neuroendocrine tumours. Health Qual Life Outcomes. 2016;14:127. [PMID: 27614762 DOI: 10.1186/s12955-016-0527-2] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 4.8] [Reference Citation Analysis]
76 Olson RA, Howard F, Lapointe V, Schellenberg D, Nichol A, Bowering G, Curtis S, Walter A, Brown S, Thompson C, Bergin J, Lomas S, French J, Halperin R, Tyldesley S, Beckham W. Provincial development of a patient-reported outcome initiative to guide patient care, quality improvement, and research. Healthc Manage Forum 2018;31:13-7. [PMID: 29264976 DOI: 10.1177/0840470417715478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
77 Gadisa DA, Wang SH, Yimer G. The Impact of AC and AC-T Chemotherapy's Toxicities on Quality of Life Among Women with Breast Cancer in Ethiopia: A Prospective Patient-Reported Outcomes Study. Breast Cancer (Dove Med Press) 2021;13:107-32. [PMID: 33658844 DOI: 10.2147/BCTT.S289014] [Reference Citation Analysis]
78 Atkinson TM, Andreotti CF, Roberts KE, Saracino RM, Hernandez M, Basch E. The level of association between functional performance status measures and patient-reported outcomes in cancer patients: a systematic review. Support Care Cancer 2015;23:3645-52. [PMID: 26314706 DOI: 10.1007/s00520-015-2923-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 25] [Article Influence: 5.2] [Reference Citation Analysis]
79 Gadisa DA, Assefa M, Tefera GM, Yimer G. Patterns of Anthracycline-Based Chemotherapy-Induced Adverse Drug Reactions and Their Impact on Relative Dose Intensity among Women with Breast Cancer in Ethiopia: A Prospective Observational Study. J Oncol 2020;2020:2636514. [PMID: 32148494 DOI: 10.1155/2020/2636514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Thanarajasingam G, Minasian LM, Baron F, Cavalli F, De Claro RA, Dueck AC, El-Galaly TC, Everest N, Geissler J, Gisselbrecht C, Gribben J, Horowitz M, Ivy SP, Jacobson CA, Keating A, Kluetz PG, Krauss A, Kwong YL, Little RF, Mahon FX, Matasar MJ, Mateos MV, McCullough K, Miller RS, Mohty M, Moreau P, Morton LM, Nagai S, Rule S, Sloan J, Sonneveld P, Thompson CA, Tzogani K, van Leeuwen FE, Velikova G, Villa D, Wingard JR, Wintrich S, Seymour JF, Habermann TM. Beyond maximum grade: modernising the assessment and reporting of adverse events in haematological malignancies. Lancet Haematol 2018;5:e563-98. [PMID: 29907552 DOI: 10.1016/S2352-3026(18)30051-6] [Cited by in Crossref: 51] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
81 Nyrop KA, Deal AM, Reeve BB, Basch E, Chen YT, Park JH, Shachar SS, Carey LA, Reeder-Hayes KE, Dees EC, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Lee JT, Wood WA, Muss HB. Congruence of patient- and clinician-reported toxicity in women receiving chemotherapy for early breast cancer. Cancer 2020;126:3084-93. [PMID: 32315091 DOI: 10.1002/cncr.32898] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
82 Lapen K, Sabol C, Tin AL, Lynch K, Kassa A, Mabli X, Ford J, Cha E, Bernstein MB, Braunstein LZ, Cahlon O, Daly BM, Sandler K, McCloskey SA, Vickers AJ, Khan AJ, Gillespie EF. Development and Pilot Implementation of a Remote Monitoring System for Acute Toxicity Using Electronic Patient-Reported Outcomes for Patients Undergoing Radiation Therapy for Breast Cancer. Int J Radiat Oncol Biol Phys 2021:S0360-3016(21)02562-1. [PMID: 34314814 DOI: 10.1016/j.ijrobp.2021.07.1692] [Reference Citation Analysis]
83 Efficace F, Gaidano G, Lo-coco F. Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice? Blood 2017;130:859-66. [DOI: 10.1182/blood-2017-03-737403] [Cited by in Crossref: 38] [Cited by in F6Publishing: 25] [Article Influence: 9.5] [Reference Citation Analysis]
84 Baeksted C, Pappot H, Nissen A, Hjollund NH, Mitchell SA, Basch E, Bidstrup PE, Dalton SO, Johansen C. Feasibility and acceptability of electronic symptom surveillance with clinician feedback using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE) in Danish prostate cancer patients. J Patient Rep Outcomes 2017;1:1. [PMID: 29757324 DOI: 10.1186/s41687-017-0005-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 5.5] [Reference Citation Analysis]
85 Trafalis DT, Alifieris C, Stathopoulos GP, Sitaras N. Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemother Pharmacol 2016;77:713-22. [PMID: 26891956 DOI: 10.1007/s00280-016-2983-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
86 Rein A, Simpson LA. Finding "truth" across different data sources. Isr J Health Policy Res 2017;6:14. [PMID: 28344767 DOI: 10.1186/s13584-017-0138-3] [Reference Citation Analysis]
87 Unger JM, Vaidya R, Gore JL. Key design and analysis principles for quality of life and patient-reported outcomes in clinical trials. Urol Oncol 2019;37:324-30. [PMID: 29572075 DOI: 10.1016/j.urolonc.2018.02.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
88 Bryant AL, Coffman E, Phillips B, Tan X, Bullard E, Hirschey R, Bradley J, Bennett AV, Stover AM, Song L, Shea TC, Wood WA. Pilot randomized trial of an electronic symptom monitoring and reporting intervention for hospitalized adults undergoing hematopoietic stem cell transplantation. Support Care Cancer 2020;28:1223-31. [PMID: 31222392 DOI: 10.1007/s00520-019-04932-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
89 Sullivan PW, Ghushchyan VH, Globe G, Sucher B. Health-related quality of life associated with systemic corticosteroids. Qual Life Res 2017;26:1037-58. [PMID: 27757775 DOI: 10.1007/s11136-016-1435-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
90 Hao Y, Krohe M, Yaworsky A, L Shields A, Mazar I, Foley C, Globe D. Clinical Trial Patient-reported Outcomes Data: Going Beyond the Label in Oncology. Clin Ther 2016;38:811-20. [PMID: 27036873 DOI: 10.1016/j.clinthera.2016.03.010] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
91 Stover AM, Basch EM. The Potential Role of Symptom Questionnaires in Palliative and Supportive Cancer Care Delivery. Curr Oncol Rep 2017;19:12. [PMID: 28220450 DOI: 10.1007/s11912-017-0571-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
92 Bossi P, Giusti R, Tarsitano A, Airoldi M, De Sanctis V, Caspiani O, Alterio D, Tartaro T, Alfieri S, Siano M. The point of pain in head and neck cancer. Crit Rev Oncol Hematol 2019;138:51-9. [PMID: 31092385 DOI: 10.1016/j.critrevonc.2019.04.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
93 Maguire R, Kotronoulas G, Donnan PT, Paterson C, McCann L, Connaghan J, Di Domenico DGG, Kearney N. Development and preliminary testing of a brief clinical tool to enable daily monitoring of chemotherapy toxicity: The Daily Chemotherapy Toxicity self-Assessment Questionnaire. Eur J Cancer Care (Engl) 2018;27:e12890. [PMID: 29993150 DOI: 10.1111/ecc.12890] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
94 Gnanasakthy A, DeMuro C, Clark M, Haydysch E, Ma E, Bonthapally V. Patient-Reported Outcomes Labeling for Products Approved by the Office of Hematology and Oncology Products of the US Food and Drug Administration (2010-2014). J Clin Oncol 2016;34:1928-34. [PMID: 27069082 DOI: 10.1200/JCO.2015.63.6480] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 6.2] [Reference Citation Analysis]
95 Knoerl R. CE: Chemotherapy-Induced Peripheral Neuropathy. Am J Nurs 2021;121:26-30. [PMID: 33735114 DOI: 10.1097/01.NAJ.0000742060.56042.e7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Stover AM, Tompkins Stricker C, Hammelef K, Henson S, Carr P, Jansen J, Deal AM, Bennett AV, Basch EM. Using Stakeholder Engagement to Overcome Barriers to Implementing Patient-reported Outcomes (PROs) in Cancer Care Delivery: Approaches From 3 Prospective Studies. Med Care 2019;57 Suppl 5 Suppl 1:S92-9. [PMID: 30985602 DOI: 10.1097/MLR.0000000000001103] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 20.0] [Reference Citation Analysis]
97 Basch E, Rogak LJ, Dueck AC. Methods for Implementing and Reporting Patient-reported Outcome (PRO) Measures of Symptomatic Adverse Events in Cancer Clinical Trials. Clin Ther 2016;38:821-30. [PMID: 27045992 DOI: 10.1016/j.clinthera.2016.03.011] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 11.2] [Reference Citation Analysis]
98 Na-Bangchang K, Plengsuriyakarn T, Karbwang J. Research and Development of Atractylodes lancea (Thunb) DC. as a Promising Candidate for Cholangiocarcinoma Chemotherapeutics. Evid Based Complement Alternat Med 2017;2017:5929234. [PMID: 29348769 DOI: 10.1155/2017/5929234] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
99 Møller PK, Pappot H, Bernchou U, Schytte T, Dieperink KB. Development of patient-reported outcomes item set to evaluate acute treatment toxicity to pelvic online magnetic resonance-guided radiotherapy. J Patient Rep Outcomes 2021;5:47. [PMID: 34160732 DOI: 10.1186/s41687-021-00326-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Yanez B, Bouchard LC, Cella D, Sosman JA, Kircher SM, Mohindra NA, Cristofanilli M, Penedo FJ. Patient-centered engagement and symptom/toxicity monitoring in the new era of tumor next-generation sequencing and immunotherapy: The OncoTool and OncoPRO platforms. Cancer 2019;125:2338-44. [PMID: 31034599 DOI: 10.1002/cncr.32030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
101 Vickers M, Lee C, Tu D, Wheatley-price P, Parulekar W, Brundage M, Moore M, Au H, O'callaghan C, Jonker D, Ringash J, Goldstein D. Significance of baseline and change in quality of life scores in predicting clinical outcomes in an international phase III trial of advanced pancreatic cancer: NCIC CTG PA.3. Pancreatology 2016;16:1106-12. [DOI: 10.1016/j.pan.2016.08.013] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
102 Streefkerk N, Tissing WJE, van der Heiden-van der Loo M, Lieke Feijen EAM, van Dulmen-den Broeder E, Loonen JJ, van der Pal HJH, Ronckers CM, van Santen HM, van den Berg MH, Mulder RL, Korevaar JC, Kremer LCM. The Dutch LATER physical outcomes set for self-reported data in survivors of childhood cancer. J Cancer Surviv 2020;14:666-76. [PMID: 32363495 DOI: 10.1007/s11764-020-00880-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
103 Simon BA, Assel MJ, Tin AL, Desai P, Stabile C, Baron RH, Cracchiolo JR, Twersky RS, Vickers AJ, Laudone VP. Association Between Electronic Patient Symptom Reporting With Alerts and Potentially Avoidable Urgent Care Visits After Ambulatory Cancer Surgery. JAMA Surg 2021;156:740-6. [PMID: 34076691 DOI: 10.1001/jamasurg.2021.1798] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
104 Stabile C, Temple LK, Ancker JS, Basch E, Carter J, Miranda M, Stein D, Stetson PD, Vickers A, Simon BA, Pusic AL. Ambulatory cancer care electronic symptom self-reporting (ACCESS) for surgical patients: a randomised controlled trial protocol. BMJ Open 2019;9:e030863. [PMID: 31530612 DOI: 10.1136/bmjopen-2019-030863] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
105 Steffen McLouth LE, Lycan TW Jr, Levine BJ, Gabbard J, Ruiz J, Farris M, Grant SC, Pajewski NM, Weaver KE, Petty WJ. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice. Clin Lung Cancer 2020;21:255-263.e4. [PMID: 31917067 DOI: 10.1016/j.cllc.2019.11.015] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
106 Penalba V, Deshields TL, Klinkenberg D. Gaps in communication between cancer patients and healthcare providers: symptom distress and patients' intentions to disclose. Support Care Cancer 2019;27:2039-47. [PMID: 30220028 DOI: 10.1007/s00520-018-4442-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
107 Gettinger SN, Redman MW, Bazhenova L, Hirsch FR, Mack PC, Schwartz LH, Bradley JD, Stinchcombe TE, Leighl NB, Ramalingam SS, Tavernier SS, Yu H, Unger JM, Minichiello K, Highleyman L, Papadimitrakopoulou VA, Kelly K, Gandara DR, Herbst RS. Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial. JAMA Oncol 2021. [PMID: 34264316 DOI: 10.1001/jamaoncol.2021.2209] [Reference Citation Analysis]
108 Zhong X, Lim EA, Hershman DL, Moinpour CM, Unger J, Lee SM. Identifying Severe Adverse Event Clusters Using the National Cancer Institute's Common Terminology Criteria for Adverse Events. J Oncol Pract 2016;12:e270-80, 245-6. [PMID: 26907453 DOI: 10.1200/JOP.2015.006106] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
109 Alifieris CE, Griniatsos J, Delis SG, Nikolaou M, Avgoustou C, Panagiotidis MI, Souferi-chronopoulou E, Trafalis DT. Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas. American Journal of Clinical Oncology 2020;43:305-10. [DOI: 10.1097/coc.0000000000000668] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
110 Kennedy F, Absolom K, Clayton B, Rogers Z, Gordon K, O'Connell Francischetto E, Blazeby JM, Brown J, Velikova G. Electronic Patient Reporting of Adverse Events and Quality of Life: A Prospective Feasibility Study in General Oncology. JCO Oncol Pract 2021;17:e386-96. [PMID: 32853122 DOI: 10.1200/OP.20.00118] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
111 Chastenet M, Laurain PA, Salleron J, Beuzeboc P, Scotté F. The Supportive Care sCore (SCC): trigger alert validation study in solid tumours. BMJ Support Palliat Care 2021:bmjspcare-2020-002716. [PMID: 33888489 DOI: 10.1136/bmjspcare-2020-002716] [Reference Citation Analysis]
112 Andersen KM, Cheah JT, March L, Bartlett SJ, Beaton D, Bingham CO, Brooks PM, Christensen R, Conaghan PG, D’agostino M, de Wit M, Dueck AC, Goodman SM, Grosskleg S, Hill CL, Howell M, Mackie SL, Richards B, Shea B, Singh JA, Strand V, Tugwell P, Wells GA, Simon LS. Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. J Rheumatol 2019;46:1053-8. [DOI: 10.3899/jrheum.181123] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
113 Skalicky AM, Ghate SR, Perez JR, Rentz AM. Results of a Qualitative Study to Develop a Patient Reported Outcome Measure for Patients with 4 Subtypes of Soft Tissue Sarcoma. Sarcoma 2017;2017:6868030. [PMID: 28588396 DOI: 10.1155/2017/6868030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
114 Pappot H, Baeksted C, Knoop A, Mitchell SA, Nissen A, Johansen C. Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology C. Breast J 2019;25:269-72. [DOI: 10.1111/tbj.13204] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
115 Masukawa K, Sato K, Shimizu M, Morita T, Miyashita M. Cancer Care Evaluation Scale (CCES): measuring the quality of the structure and process of cancer care from the perspective of patients with cancer. Jpn J Clin Oncol 2021;51:92-9. [PMID: 32888002 DOI: 10.1093/jjco/hyaa165] [Reference Citation Analysis]
116 Tykodi SS, Schadendorf D, Cella D, Reck M, Harrington K, Wagner S, Shaw JW. Patient-reported outcomes with nivolumab in advanced solid cancers. Cancer Treat Rev 2018;70:75-87. [PMID: 30125799 DOI: 10.1016/j.ctrv.2018.08.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
117 Hudson MM, Ehrhardt MJ, Bhakta N, Baassiri M, Eissa H, Chemaitilly W, Green DM, Mulrooney DA, Armstrong GT, Brinkman TM, Klosky JL, Krull KR, Sabin ND, Wilson CL, Huang IC, Bass JK, Hale K, Kaste S, Khan RB, Srivastava DK, Yasui Y, Joshi VM, Srinivasan S, Stokes D, Hoehn ME, Wilson M, Ness KK, Robison LL. Approach for Classification and Severity Grading of Long-term and Late-Onset Health Events among Childhood Cancer Survivors in the St. Jude Lifetime Cohort. Cancer Epidemiol Biomarkers Prev 2017;26:666-74. [PMID: 28035022 DOI: 10.1158/1055-9965.EPI-16-0812] [Cited by in Crossref: 104] [Cited by in F6Publishing: 58] [Article Influence: 20.8] [Reference Citation Analysis]
118 Johannsdottir IMR, Hamre H, Fosså SD, Loge JH, Drolsum L, Lund MB, Nordsletten L, Kiserud C. Adverse Health Outcomes and Associations with Self-Reported General Health in Childhood Lymphoma Survivors. J Adolesc Young Adult Oncol 2017;6:470-6. [PMID: 28837384 DOI: 10.1089/jayao.2017.0018] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
119 Arnold B, Mitchell SA, Lent L, Mendoza TR, Rogak LJ, Barragán NM, Willis G, Medina M, Lechner S, Penedo FJ, Harness JK, Basch EM; PRO-CTCAE Spanish Translation and Linguistic Validation Study Group. Linguistic validation of the Spanish version of the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Support Care Cancer 2016;24:2843-51. [PMID: 26838022 DOI: 10.1007/s00520-015-3062-5] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
120 Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-Reported Outcomes in Cancer Clinical Trials: Measuring Symptomatic Adverse Events With the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Am Soc Clin Oncol Educ Book 2016;35:67-73. [PMID: 27249687 DOI: 10.1200/EDBK_159514] [Cited by in Crossref: 88] [Cited by in F6Publishing: 44] [Article Influence: 22.0] [Reference Citation Analysis]
121 Bergerot CD, Philip EJ, Bergerot PG, Hsu J, Dizman N, Salgia M, Salgia N, Vaishampayan U, Battle D, Loscalzo M, Dale W, Pal SK. Discrepancies between genitourinary cancer patients' and clinicians' characterization of the Eastern Cooperative Oncology Group performance status. Cancer 2021;127:354-8. [PMID: 33007114 DOI: 10.1002/cncr.33238] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
122 Fiero MH, Roydhouse JK, Vallejo J, King-Kallimanis BL, Kluetz PG, Sridhara R. US Food and Drug Administration review of statistical analysis of patient-reported outcomes in lung cancer clinical trials approved between January, 2008, and December, 2017. Lancet Oncol 2019;20:e582-9. [PMID: 31579004 DOI: 10.1016/S1470-2045(19)30335-3] [Cited by in Crossref: 14] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
123 Armstrong TS, Vera-Bolanos E, Acquaye AA, Gilbert MR, Ladha H, Mendoza T. The symptom burden of primary brain tumors: evidence for a core set of tumor- and treatment-related symptoms. Neuro Oncol 2016;18:252-60. [PMID: 26289592 DOI: 10.1093/neuonc/nov166] [Cited by in Crossref: 49] [Cited by in F6Publishing: 27] [Article Influence: 8.2] [Reference Citation Analysis]
124 Lobach DF, Johns EB, Halpenny B, Saunders TA, Brzozowski J, Del Fiol G, Berry DL, Braun IM, Finn K, Wolfe J, Abrahm JL, Cooley ME. Increasing Complexity in Rule-Based Clinical Decision Support: The Symptom Assessment and Management Intervention. JMIR Med Inform 2016;4:e36. [PMID: 27826132 DOI: 10.2196/medinform.5728] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 2.6] [Reference Citation Analysis]
125 Thieblemont C, Howlett S, Casasnovas RO, Mounier N, Perrot A, Morschhauser F, Fruchart C, Daguindau N, van Eygen K, Obéric L, Bouabdallah R, Pica GM, Nicolas-Virezelier E, Abraham J, Fitoussi O, Snauwaert S, Eisenmann JC, Lionne-Huyghe P, Bron D, Tricot S, Deeren D, Gonzalez H, Costello R, Le Du K, da Silva MG, Grosicki S, Trotman J, Catalano J, Caballero D, Greil R, Cohen AM, Gaulard P, Roulin L, Takeshita K, Casadebaig ML, Tilly H, Coiffier B. Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. Br J Haematol 2020;189:84-96. [PMID: 31702836 DOI: 10.1111/bjh.16300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
126 Hall E, Tam E, Liang M, Zhang Q, Liu L, Wong L, Sarabia S, Yeung S, Gill G, Eng L, Perez-Cosio A, Brown MC, Xu W, Li M, Mittmann N, Jones J, Howell D, Liu G. Development and prospective evaluation of CAPLET, a cancer ambulatory patient physical function longitudinal evaluation tool for routine clinical practice. Support Care Cancer 2019;27:521-30. [PMID: 29982902 DOI: 10.1007/s00520-018-4333-8] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
127 Chen JL, Shen C, Wang C, Huang Y, Chen J, Chiang C, Lin Y, Kuo S, Wang C. Impact of smoking cessation on clinical outcomes in patients with head and neck squamous cell carcinoma receiving curative chemoradiotherapy: A prospective study. Head & Neck 2019;41:3201-10. [DOI: 10.1002/hed.25814] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
128 Fogh SE, Deshmukh S, Berk LB, Dueck AC, Roof K, Yacoub S, Gergel T, Stephans K, Rimner A, DeNittis A, Pablo J, Rineer J, Williams TM, Bruner D. A Randomized Phase 2 Trial of Prophylactic Manuka Honey for the Reduction of Chemoradiation Therapy-Induced Esophagitis During the Treatment of Lung Cancer: Results of NRG Oncology RTOG 1012. Int J Radiat Oncol Biol Phys 2017;97:786-96. [PMID: 28244415 DOI: 10.1016/j.ijrobp.2016.11.022] [Cited by in Crossref: 27] [Cited by in F6Publishing: 14] [Article Influence: 5.4] [Reference Citation Analysis]
129 Su SY, Bell D, Ferrarotto R, Phan J, Roberts D, Kupferman ME, Frank SJ, Fuller CD, Gunn GB, Kies MS, Glisson BS, Hanna EY. Outcomes for olfactory neuroblastoma treated with induction chemotherapy. Head Neck 2017;39:1671-9. [PMID: 28561956 DOI: 10.1002/hed.24822] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 8.3] [Reference Citation Analysis]
130 Taarnhøj GA, Lindberg H, Dohn LH, Omland LH, Hjøllund NH, Johansen C, Pappot H. Electronic reporting of patient-reported outcomes in a fragile and comorbid population during cancer therapy - a feasibility study. Health Qual Life Outcomes 2020;18:225. [PMID: 32653005 DOI: 10.1186/s12955-020-01480-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
131 LeBlanc TW, Abernethy AP. Patient-reported outcomes in cancer care - hearing the patient voice at greater volume. Nat Rev Clin Oncol 2017;14:763-72. [PMID: 28975931 DOI: 10.1038/nrclinonc.2017.153] [Cited by in Crossref: 83] [Cited by in F6Publishing: 48] [Article Influence: 20.8] [Reference Citation Analysis]
132 Gilbert A, Ziegler L, Martland M, Davidson S, Efficace F, Sebag-montefiore D, Velikova G. Systematic Review of Radiation Therapy Toxicity Reporting in Randomized Controlled Trials of Rectal Cancer: A Comparison of Patient-Reported Outcomes and Clinician Toxicity Reporting. International Journal of Radiation Oncology*Biology*Physics 2015;92:555-67. [DOI: 10.1016/j.ijrobp.2015.02.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 5.5] [Reference Citation Analysis]
133 Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, Haderlein M, Weissmann T, Semrau S, Gostian AO, Müller SK, Traxdorf M, Iro H, Zhou JG, Gaipl US, Fietkau R, Hecht M. Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. BMC Cancer 2021;21:314. [PMID: 33761922 DOI: 10.1186/s12885-021-08006-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
134 Schuurhuizen CS, Verheul HM, Braamse AM, Buffart LM, Bloemendal HJ, Dekker J, Konings IR. The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy. Cancer Manag Res 2018;10:3015-21. [PMID: 30214296 DOI: 10.2147/CMAR.S166468] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
135 Basch E, Dueck AC, Rogak LJ, Mitchell SA, Minasian LM, Denicoff AM, Wind JK, Shaw MC, Heon N, Shi Q, Ginos B, Nelson GD, Meyers JP, Chang GJ, Mamon HJ, Weiser MR, Kolevska T, Reeve BB, Bruner DW, Schrag D. Feasibility of Implementing the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events in a Multicenter Trial: NCCTG N1048. J Clin Oncol 2018;:JCO2018788620. [PMID: 30204536 DOI: 10.1200/JCO.2018.78.8620] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 8.3] [Reference Citation Analysis]
136 Mihaljevic AL; CHIR-Net SIGMA Study Group*. Multicenter Prospective Cohort Study of the Patient-Reported Outcome Measures PRO-CTCAE and CAT EORTC QLQ-C30 in Major Abdominal Cancer Surgery (PATRONUS): A Student-Initiated German Medical Audit (SIGMA) Study. Ann Surg Oncol 2021;28:3075-89. [PMID: 33683524 DOI: 10.1245/s10434-021-09646-z] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
137 Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, Hwang ES, Bliss JM, Rakovitch E, Perlmutter J, Spears PA, Frank E, Tung NM, Elias AD, Cameron D, Denduluri N, Best AF, DiLeo A, Baizer L, Butler LP, Schwartz E, Winer EP, Korde LA. Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. J Clin Oncol 2021;39:2720-31. [PMID: 34003702 DOI: 10.1200/JCO.20.03613] [Reference Citation Analysis]
138 Rioth MJ, Warner J, Savani BN, Jagasia M. Next-generation long-term transplant clinics: improving resource utilization and the quality of care through health information technology. Bone Marrow Transplant 2016;51:34-40. [PMID: 26367235 DOI: 10.1038/bmt.2015.210] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
139 Atkinson TM, Hay JL, Shoushtari A, Li Y, Paucar DJ, Smith SC, Kudchadkar RR, Doyle A, Sosman JA, Quevedo JF, Milhem MM, Joshua AM, Linette GP, Gajewski TF, Lutzky J, Lawson DH, Lao CD, Flynn PJ, Albertini MR, Sato T, Lewis K, Marr B, Abramson DH, Dickson MA, Schwartz GK, Carvajal RD. Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma. J Cancer Res Clin Oncol 2017;143:439-45. [PMID: 27921276 DOI: 10.1007/s00432-016-2318-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
140 Song A, Bar-ad V, Martinez N, Glass J, Andrews DW, Judy K, Evans JJ, Farrell CJ, Werner-wasik M, Chervoneva I, Ly M, Palmer JD, Liu H, Shi W. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. J Neurooncol 2020;147:653-61. [DOI: 10.1007/s11060-020-03466-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
141 Pan TT, Wang W, Jia WD, Xu GL. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncol Lett 2017;13:2957-64. [PMID: 28529557 DOI: 10.3892/ol.2017.5847] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
142 Berthelsen DB, Woodworth TG, Goel N, Ioannidis JPA, Tugwell P, Devoe D, Williamson P, Terwee CB, Suarez-Almazor ME, Strand V, Leong AL, Conaghan PG, Boers M, Shea BJ, Brooks PM, Simon LS, Furst DE, Christensen R; OMERACT Safety Working Group. Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. Semin Arthritis Rheum 2021;51:607-17. [PMID: 33483129 DOI: 10.1016/j.semarthrit.2020.09.023] [Reference Citation Analysis]
143 Visvanathan K, Levit LA, Raghavan D, Hudis CA, Wong S, Dueck A, Lyman GH. Untapped Potential of Observational Research to Inform Clinical Decision Making: American Society of Clinical Oncology Research Statement. JCO 2017;35:1845-54. [DOI: 10.1200/jco.2017.72.6414] [Cited by in Crossref: 61] [Cited by in F6Publishing: 16] [Article Influence: 15.3] [Reference Citation Analysis]
144 Ellis GK, Chapman H, Manda A, Salima A, Itimu S, Banda G, Seguin R, Manda G, Butia M, Huibers M, Ozuah N, Tilly A, Stover AM, Basch E, Gopal S, Reeve BB, Westmoreland KD. Pediatric lymphoma patients in Malawi present with poor health-related quality of life at diagnosis and improve throughout treatment and follow-up across all Pediatric PROMIS-25 domains. Pediatr Blood Cancer 2021;68:e29257. [PMID: 34339099 DOI: 10.1002/pbc.29257] [Reference Citation Analysis]
145 Selby P, Popescu R, Lawler M, Butcher H, Costa A. The Value and Future Developments of Multidisciplinary Team Cancer Care. American Society of Clinical Oncology Educational Book 2019. [DOI: 10.1200/edbk_236857] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 9.5] [Reference Citation Analysis]
146 Joly F, Hilpert F, Okamoto A, Stuart G, Ochiai K, Friedlander M. Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: Recommendations on incorporating patient-reported outcomes in clinical trials in epithelial ovarian cancer. European Journal of Cancer 2017;78:133-8. [DOI: 10.1016/j.ejca.2017.03.019] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 5.5] [Reference Citation Analysis]
147 Piccinin C, Pe M, Kuliś D, Shaw JW, Wheelwright SJ, Bottomley A. Equivalence testing of a newly developed interviewer-led telephone script for the EORTC QLQ-C30. Qual Life Res 2021. [PMID: 34286416 DOI: 10.1007/s11136-021-02955-6] [Reference Citation Analysis]
148 Voon PJ, Cella D, Hansen AR. Health-related quality-of-life assessment of patients with solid tumors on immuno-oncology therapies. Cancer 2021;127:1360-8. [PMID: 33662145 DOI: 10.1002/cncr.33457] [Reference Citation Analysis]
149 Knoerl R, Smith EML, Han A, Doe A, Scott K, Berry DL. Characterizing patient-clinician chemotherapy-induced peripheral neuropathy assessment and management communication approaches. Patient Educ Couns 2019;102:1636-43. [PMID: 31003878 DOI: 10.1016/j.pec.2019.04.012] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
150 Tannock IF, Amir E, Booth CM, Niraula S, Ocana A, Seruga B, Templeton AJ, Vera-Badillo F. Relevance of randomised controlled trials in oncology. Lancet Oncol 2016;17:e560-7. [PMID: 27924754 DOI: 10.1016/S1470-2045(16)30572-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 11] [Article Influence: 9.5] [Reference Citation Analysis]
151 Hack SP, Verret W, Mulla S, Liu B, Wang Y, Macarulla T, Ren Z, El-Khoueiry AB, Zhu AX. IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer. Ther Adv Med Oncol 2021;13:17588359211036544. [PMID: 34377158 DOI: 10.1177/17588359211036544] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
152 Jin WH, Mellon EA, Frakes JM, Murimwa GZ, Hodul PJ, Pimiento JM, Malafa MP, Hoffe SE. Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy. J Gastrointest Oncol 2018;9:24-34. [PMID: 29564168 DOI: 10.21037/jgo.2017.09.13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
153 Knoerl R, Lee D, Yang J, Bridges C, Kanzawa-Lee G, Lita Smith G, Lavoie Smith EM. Examining the Impact of a Web-Based Intervention to Promote Patient Activation in Chemotherapy-Induced Peripheral Neuropathy Assessment and Management. J Cancer Educ 2018;33:1027-35. [PMID: 28265863 DOI: 10.1007/s13187-017-1200-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
154 Cristaudo A, Hickman M, Fong C, Sanghera P, Hartley A. Assessing Novel Drugs and Radiation Technology in the Chemoradiation of Oropharyngeal Cancer. Medicines (Basel) 2018;5:E65. [PMID: 29954154 DOI: 10.3390/medicines5030065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
155 Schmalz O, Jacob C, Ammann J, Liss B, Iivanainen S, Kammermann M, Koivunen J, Klein A, Popescu RA. Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients. J Med Internet Res 2020;22:e18655. [PMID: 33346738 DOI: 10.2196/18655] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
156 Deng S, Yang Q, Shu X, Lang J, Lu S. The Relative Risk of Immune-Related Liver Dysfunction of PD-1/PD-L1 Inhibitors Versus Chemotherapy in Solid Tumors: A Meta-Analysis of Randomized Controlled Trials. Front Pharmacol. 2019;10:1063. [PMID: 31607917 DOI: 10.3389/fphar.2019.01063] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
157 Basch E, Wood WA, Schrag D, Sima CS, Shaw M, Rogak LJ, Kris MG, Shouery M, Bennett A, Atkinson T, Pietanza MC. Feasibility and clinical impact of sharing patient-reported symptom toxicities and performance status with clinical investigators during a phase 2 cancer treatment trial. Clin Trials 2016;13:331-7. [PMID: 26542025 DOI: 10.1177/1740774515615540] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
158 Knoerl R, Gilchrist L, Kanzawa-lee GA, Donohoe C, Bridges C, Lavoie Smith EM. Proactive Rehabilitation for Chemotherapy-Induced Peripheral Neuropathy. Seminars in Oncology Nursing 2020;36:150983. [DOI: 10.1016/j.soncn.2019.150983] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
159 Schmulenson E, Krolop L, Simons S, Ringsdorf S, Ko YD, Jaehde U. Evaluation of patient-reported severity of hand-foot syndrome under capecitabine using a Markov modeling approach. Cancer Chemother Pharmacol 2020;86:435-44. [PMID: 32852627 DOI: 10.1007/s00280-020-04128-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
160 Galizia D, Milani A, Geuna E, Martinello R, Cagnazzo C, Foresto M, Longo V, Berchialla P, Solinas G, Calori A, Grasso B, Volpone C, Bertola G, Parola G, Tealdi G, Giuliano PL, Ballari AM, Aglietta M, Montemurro F. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. Cancer Med 2018;7:4339-44. [PMID: 30030895 DOI: 10.1002/cam4.1687] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
161 Henon C, Lissa D, Paoletti X, Thibault C, Le Tourneau C, Lanoy E, Hollebecque A, Massard C, Soria JC, Postel-Vinay S. Patient-reported tolerability of adverse events in phase 1 trials. ESMO Open 2017;2:e000148. [PMID: 28761740 DOI: 10.1136/esmoopen-2016-000148] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
162 Knoerl R, Mazzola E, Hong F, Salehi E, McCleary N, Ligibel J, Reyes K, Berry DL. Exploring the impact of a decision support algorithm to improve clinicians' chemotherapy-induced peripheral neuropathy assessment and management practices: a two-phase, longitudinal study. BMC Cancer 2021;21:236. [PMID: 33676431 DOI: 10.1186/s12885-021-07965-8] [Reference Citation Analysis]
163 Craig BM, Mitchell SA. Examining the Value of Menopausal Symptom Relief Among US Women. Value Health 2016;19:158-66. [PMID: 27021749 DOI: 10.1016/j.jval.2015.11.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
164 Cabarrou B, Boher JM, Bogart E, Tresch-Bruneel E, Penel N, Ravaud A, Escudier B, Mahier Ait-Oukhatar C, Delord JP, Roché H, Filleron T. How to report toxicity associated with targeted therapies? Ann Oncol 2016;27:1633-8. [PMID: 27217543 DOI: 10.1093/annonc/mdw218] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
165 Miller TP, Aplenc R. Evolution of Hematology Clinical Trial Adverse Event Reporting to Improve Care Delivery. Curr Hematol Malig Rep 2021;16:126-31. [PMID: 33786724 DOI: 10.1007/s11899-021-00627-3] [Reference Citation Analysis]
166 Armbrust R, Alavi S, Pirmorady A, Chen F, Colombo N, Gultekin M, Hierro C, Lemley B, Mirza MR, Urkmez E, Fotopoulou C, Vinzent J, Gonzalez Martin A, Krull A, Heepe J, Rose M, Sehouli J. Results of the interprofessional and interdisciplinary Berlin round table on patient-reported outcomes, quality of life, and treatment expectations of patients with gynecological cancer under maintenance treatment. Int J Gynecol Cancer 2020;30:1603-7. [PMID: 32817309 DOI: 10.1136/ijgc-2019-001070] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE. KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study. Leuk Res 2016;50:123-31. [PMID: 27736729 DOI: 10.1016/j.leukres.2016.09.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 6.2] [Reference Citation Analysis]
168 Marandino L, Necchi A, Aglietta M, Di Maio M. COVID-19 Emergency and the Need to Speed Up the Adoption of Electronic Patient-Reported Outcomes in Cancer Clinical Practice. JCO Oncol Pract 2020;16:295-8. [PMID: 32364846 DOI: 10.1200/OP.20.00237] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 13.0] [Reference Citation Analysis]
169 Fish R, Sanders C, Adams R, Brewer J, Brookes ST, DeNardo J, Kochhar R, Saunders MP, Sebag-Montefiore D, Williamson PR, Renehan AG. A core outcome set for clinical trials of chemoradiotherapy interventions for anal cancer (CORMAC): a patient and health-care professional consensus. Lancet Gastroenterol Hepatol 2018;3:865-73. [PMID: 30507470 DOI: 10.1016/S2468-1253(18)30264-4] [Cited by in Crossref: 30] [Cited by in F6Publishing: 11] [Article Influence: 15.0] [Reference Citation Analysis]
170 Chien TJ, Liu CY, Lu RH, Kuo CW, Lin YC, Hsu CH. Therapeutic efficacy of Traditional Chinese medicine, "Kuan-Sin-Yin", in patients undergoing chemotherapy for advanced colon cancer - A controlled trial. Complement Ther Med 2016;29:204-12. [PMID: 27912948 DOI: 10.1016/j.ctim.2016.10.001] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
171 Alberti P, Cavaletti G, Cornblath DR. Toxic neuropathies: Chemotherapy Induced Peripheral Neurotoxicity. Current Opinion in Neurology 2019;32:676-83. [DOI: 10.1097/wco.0000000000000724] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
172 Nyrop KA, Deal AM, Chen YT, Reeve BB, Basch EM, Wood WA, Shachar SS, Carey LA, Reeder-Hayes KE, Dees EC, Jolly TA, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Lee JT, Brenizer A, Muss HB. Patient-reported symptom severity, interference with daily activities, and adverse events in older and younger women receiving chemotherapy for early breast cancer. Cancer 2021;127:957-67. [PMID: 33216355 DOI: 10.1002/cncr.33329] [Reference Citation Analysis]
173 Autrusseau PA, Cazzato RL, De Marini P, Auloge P, Koch G, Dalili D, Weiss J, Mayer T, Garnon J, Gangi A. Pain relief and local tumour control following percutaneous image-guided cryoablation for spine metastasis: a 12-year single-centre experience. Clin Radiol 2021;76:674-80. [PMID: 34120732 DOI: 10.1016/j.crad.2021.05.013] [Reference Citation Analysis]
174 Basch EM, Scholz M, de Bono JS, Vogelzang N, de Souza P, Marx G, Vaishampayan U, George S, Schwarz JK, Antonarakis ES, O'Sullivan JM, Kalebasty AR, Chi KN, Dreicer R, Hutson TE, Dueck AC, Bennett AV, Dayan E, Mangeshkar M, Holland J, Weitzman AL, Scher HI. Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint. Eur Urol 2019;75:929-37. [PMID: 30528222 DOI: 10.1016/j.eururo.2018.11.033] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 6.7] [Reference Citation Analysis]
175 de Vries ST, Wong L, Sutcliffe A, Houÿez F, Ruiz CL, Mol PG; IMI Web-RADR Work Package 3b Consortium. Factors Influencing the Use of a Mobile App for Reporting Adverse Drug Reactions and Receiving Safety Information: A Qualitative Study. Drug Saf 2017;40:443-55. [PMID: 28035492 DOI: 10.1007/s40264-016-0494-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 11] [Article Influence: 6.0] [Reference Citation Analysis]
176 Lee JY, Abugharib A, Nguyen R, Eisbruch A. Impact of xerostomia and dysphagia on health-related quality of life for head and neck cancer patients. Expert Review of Quality of Life in Cancer Care 2016;1:361-71. [DOI: 10.1080/23809000.2016.1236661] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
177 Degboe A, Knight SL, Halling K, Trigg A, Al-Zubeidi T, Aldhouse N, Kitchen H, Wirth L, Rogers SN. Patients' experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study. J Patient Rep Outcomes 2017;2:33. [PMID: 30148250 DOI: 10.1186/s41687-018-0060-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
178 Nissen A, Bager L, Pappot H. The use of PRO in adverse event identification during cancer therapy - choosing the right questions to ask. Acta Oncol 2019;58:596-602. [PMID: 30702003 DOI: 10.1080/0284186X.2018.1560496] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
179 Sebastian M, Rydén A, Walding A, Papadimitrakopoulou V. Patient-reported symptoms possibly related to treatment with osimertinib or chemotherapy for advanced non-small cell lung cancer. Lung Cancer 2018;122:100-6. [DOI: 10.1016/j.lungcan.2018.05.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
180 Rotenstein LS, Agarwal A, O'Neil K, Kelly A, Keaty M, Whitehouse C, Kalinowski B, Orio PF 3rd, Wagle N, Martin NE. Implementing patient-reported outcome surveys as part of routine care: lessons from an academic radiation oncology department. J Am Med Inform Assoc 2017;24:964-8. [PMID: 28339771 DOI: 10.1093/jamia/ocx009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
181 Schrag D, Weiser M, Saltz L, Mamon H, Gollub M, Basch E, Venook A, Shi Q. Challenges and solutions in the design and execution of the PROSPECT Phase II/III neoadjuvant rectal cancer trial (NCCTG N1048/Alliance). Clin Trials 2019;16:165-75. [PMID: 30688523 DOI: 10.1177/1740774518824539] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
182 Anota A, Boulin M, Dabakuyo-Yonli S, Hillon P, Cercueil JP, Minello A, Jouve JL, Paoletti X, Bedenne L, Guiu B. An explorative study to assess the association between health-related quality of life and the recommended phase II dose in a phase I trial: idarubicin-loaded beads for chemoembolisation of hepatocellular carcinoma. BMJ Open. 2016;6:e010696. [PMID: 27342239 DOI: 10.1136/bmjopen-2015-010696] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
183 Brédart A, Bodson S, Le Tourneau C, Flahault C, Bonnetain F, Beaudeau A, Coquan E, Dolbeault S, Paoletti X. Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study. Eur J Cancer Care (Engl) 2017;26. [PMID: 27734561 DOI: 10.1111/ecc.12596] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
184 Stover AM, Urick BY, Deal AM, Teal R, Vu MB, Carda-Auten J, Jansen J, Chung AE, Bennett AV, Chiang A, Cleeland C, Deutsch Y, Tai E, Zylla D, Williams LA, Pitzen C, Snyder C, Reeve B, Smith T, McNiff K, Cella D, Neuss MN, Miller R, Atkinson TM, Spears PA, Smith ML, Geoghegan C, Basch EM. Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer Centers. JCO Oncol Pract 2020;16:e234-50. [PMID: 32074014 DOI: 10.1200/JOP.19.00784] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
185 Cabarrou B, Gomez-Roca C, Viala M, Rabeau A, Paulon R, Loirat D, Munsch N, Delord JP, Filleron T. Modernizing adverse events analysis in oncology clinical trials using alternative approaches: rationale and design of the MOTIVATE trial. Invest New Drugs 2020;38:1879-87. [PMID: 32383099 DOI: 10.1007/s10637-020-00938-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
186 Kim HP, Lieber SR, Rogers ME, Moon AM, Loiselle M, Walker J, Assis DN, Safer R, Gomel R, Evon DM. A Systematic Review of Patient-Reported Outcomes in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. Hepatol Commun 2020;4:1502-15. [PMID: 33024919 DOI: 10.1002/hep4.1567] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
187 Tampaki EC, Tampakis A, Alifieris CE, Krikelis D, Pazaiti A, Kontos M, Trafalis DT. Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. Clin Drug Investig 2018;38:639-48. [PMID: 29744672 DOI: 10.1007/s40261-018-0655-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 6.5] [Reference Citation Analysis]
188 Tan AC, Mccrary JM, Park SB, Trinh T, Goldstein D. Chemotherapy-induced peripheral neuropathy—patient-reported outcomes compared with NCI-CTCAE grade. Support Care Cancer 2019;27:4771-7. [DOI: 10.1007/s00520-019-04781-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
189 Dutz A, Lühr A, Agolli L, Troost EG, Krause M, Baumann M, Vermeren X, Geismar D, Schapira EF, Bussière M, Daly JE, Bussière MR, Timmermann B, Shih HA, Löck S. Development and validation of NTCP models for acute side-effects resulting from proton beam therapy of brain tumours. Radiotherapy and Oncology 2019;130:164-71. [DOI: 10.1016/j.radonc.2018.06.036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
190 Solomon DH, Glynn RJ, Karlson EW, Lu F, Corrigan C, Colls J, Xu C, MacFadyen J, Barbhaiya M, Berliner N, Dellaripa PF, Everett BM, Pradhan AD, Hammond SP, Murray M, Rao DA, Ritter SY, Rutherford A, Sparks JA, Stratton J, Suh DH, Tedeschi SK, Vanni KMM, Paynter NP, Ridker PM. Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med 2020;172:369-80. [PMID: 32066146 DOI: 10.7326/M19-3369] [Cited by in Crossref: 41] [Cited by in F6Publishing: 15] [Article Influence: 41.0] [Reference Citation Analysis]
191 Van Der Weijst L, Surmont V, Schrauwen W, Lievens Y. Real Life Data on Patient-Reported Outcomes and Neuro-Cognitive Functioning of Lung Cancer Patients: The PRO-Long Study. Front Oncol 2021;11:685605. [PMID: 34222010 DOI: 10.3389/fonc.2021.685605] [Reference Citation Analysis]
192 Mendoza TR, Dueck AC, Bennett AV, Mitchell SA, Reeve BB, Atkinson TM, Li Y, Castro KM, Denicoff A, Rogak LJ, Piekarz RL, Cleeland CS, Sloan JA, Schrag D, Basch E. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE. Clin Trials 2017;14:255-63. [PMID: 28545337 DOI: 10.1177/1740774517698645] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 7.5] [Reference Citation Analysis]
193 Miyaji T, Iioka Y, Kuroda Y, Yamamoto D, Iwase S, Goto Y, Tsuboi M, Odagiri H, Tsubota Y, Kawaguchi T, Sakata N, Basch E, Yamaguchi T. Japanese translation and linguistic validation of the US National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Patient Rep Outcomes 2017;1:8. [PMID: 29757296 DOI: 10.1186/s41687-017-0012-7] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
194 Mihaljevic AL; CHIR-Net SIGMA Study Group. ASO Author Reflections: The Magic of Clinical Research-The Student-Led PATRONUS Study Unveils Two Patient-Reported Outcome Measures for Use in Surgical Oncology. Ann Surg Oncol 2021;28:3090-1. [PMID: 33619669 DOI: 10.1245/s10434-021-09648-x] [Reference Citation Analysis]
195 Lyszczyk M, Karkhaneh M, Gladwin KK, Funabashi M, Zorzela L, Vohra S. Adverse Events of Mind-Body Interventions in Children: A Systematic Review. Children (Basel) 2021;8:358. [PMID: 33947033 DOI: 10.3390/children8050358] [Reference Citation Analysis]
196 Matsunaga T, Satio H, Miyauchi W, Shishido Y, Miyatani K, Murakami Y, Hanaki T, Kihara K, Yamamoto M, Tokuyasu N, Takano S, Sakamoto T, Hasegawa T, Fujiwara Y. Impact of skeletal muscle mass in patients with recurrent gastric cancer. World J Surg Oncol 2021;19:170. [PMID: 34116681 DOI: 10.1186/s12957-021-02283-6] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
197 Kessel KA, Diehl CD, Oechsner M, Meyer B, Gempt J, Zimmer C, Schmidt-Graf F, Combs SE. Patient-Reported Outcome (PRO) as an Addition to Long-Term Results after High-Precision Stereotactic Radiotherapy in Patients with Secreting and Non-Secreting Pituitary Adenomas: A Retrospective Cohort Study up to 17-Years Follow-Up. Cancers (Basel) 2019;11:E1884. [PMID: 31783579 DOI: 10.3390/cancers11121884] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
198 Meyer LA, Nick AM, Shi Q, Wang XS, Williams L, Brock T, Iniesta MD, Rangel K, Lu KH, Ramirez PT. Perioperative trajectory of patient reported symptoms: a pilot study in gynecologic oncology patients. Gynecol Oncol 2015;136:440-5. [PMID: 25647455 DOI: 10.1016/j.ygyno.2015.01.547] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
199 Kaasa S, Loge JH, Aapro M, Albreht T, Anderson R, Bruera E, Brunelli C, Caraceni A, Cervantes A, Currow DC, Deliens L, Fallon M, Gómez-batiste X, Grotmol KS, Hannon B, Haugen DF, Higginson IJ, Hjermstad MJ, Hui D, Jordan K, Kurita GP, Larkin PJ, Miccinesi G, Nauck F, Pribakovic R, Rodin G, Sjøgren P, Stone P, Zimmermann C, Lundeby T. Integration of oncology and palliative care: a Lancet Oncology Commission. The Lancet Oncology 2018;19:e588-653. [DOI: 10.1016/s1470-2045(18)30415-7] [Cited by in Crossref: 181] [Cited by in F6Publishing: 58] [Article Influence: 60.3] [Reference Citation Analysis]
200 Hohman R, Shea M, Kozak M, Roberts S, Allen J, Sigal E. Regulatory decision-making meets the real world. Sci Transl Med 2015;7:313fs46-313fs46. [DOI: 10.1126/scitranslmed.aad5233] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
201 Lo Dico R, Faron M, Yonemura Y, Glehen O, Pocard M, Sardi A, Hübner M, Baratti D, Liberale G, Kartheuser A, de Hingh I, Sugarbaker P, Ceelen W, Moran B, Robella M, Quenet F, Sideris L, Goere D, Limbert M, Sammartino P, Morris D; PSOGI Working Group, BIG RENAPE Working Group. Combined liver resection and cytoreductive surgery with HIPEC for metastatic colorectal cancer: Results of a worldwide analysis of 565 patients from the Peritoneal Surface Oncology Group International (PSOGI). Eur J Surg Oncol 2021;47:89-100. [PMID: 32943276 DOI: 10.1016/j.ejso.2020.07.038] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
202 Rasschaert M, Vulsteke C, De Keersmaeker S, Vandenborne K, Dias S, Verschaeve V, Vuylsteke P, Brussel IV, Ravelingien J, Dam PV, Segelov E, Peeters M. AMTRA: a multicentered experience of a web-based monitoring and tailored toxicity management system for cancer patients. Support Care Cancer 2021;29:859-67. [PMID: 32519044 DOI: 10.1007/s00520-020-05550-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
203 Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, Jewell ST, Matsoukas K, Li Y, Basch E. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 2016;24:3669-76. [PMID: 27260018 DOI: 10.1007/s00520-016-3297-9] [Cited by in Crossref: 134] [Cited by in F6Publishing: 84] [Article Influence: 26.8] [Reference Citation Analysis]
204 Reeve BB, McFatrich M, Pinheiro LC, Weaver MS, Sung L, Withycombe JS, Baker JN, Mack JW, Waldron MK, Gibson D, Tomlinson D, Freyer DR, Mowbray C, Jacobs S, Palma D, Martens CE, Gold SH, Jackson KD, Hinds PS. Eliciting the child's voice in adverse event reporting in oncology trials: Cognitive interview findings from the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events initiative. Pediatr Blood Cancer 2017;64. [PMID: 27650708 DOI: 10.1002/pbc.26261] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 6.4] [Reference Citation Analysis]
205 Taarnhøj GA, Lindberg H, Johansen C, Pappot H. Patient-Reported Outcomes, Health-Related Quality of Life, and Clinical Outcomes for Urothelial Cancer Patients Receiving Chemo- or Immunotherapy: A Real-Life Experience. J Clin Med 2021;10:1852. [PMID: 33923176 DOI: 10.3390/jcm10091852] [Reference Citation Analysis]
206 Atkinson TM, Reeve BB, Dueck AC, Bennett AV, Mendoza TR, Rogak LJ, Basch E, Li Y. Application of a Bayesian graded response model to characterize areas of disagreement between clinician and patient grading of symptomatic adverse events. J Patient Rep Outcomes 2018;2:56. [PMID: 30515599 DOI: 10.1186/s41687-018-0086-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
207 Kirchheiner K, Pötter R, Nout RA, Schwartz-Vittrup A, Holzner B, Bentzen SM, Tanderup K. Late, Persistent, Substantial, Treatment-Related Symptoms After Radiation Therapy (LAPERS): A New Method for Longitudinal Analysis of Late Morbidity-Applied in the EMBRACE Study. Int J Radiat Oncol Biol Phys 2020;106:300-9. [PMID: 31669565 DOI: 10.1016/j.ijrobp.2019.10.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
208 Nyrop KA, Deal AM, Shachar SS, Basch E, Reeve BB, Choi SK, Lee JT, Wood WA, Anders CK, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Kimmick GG, Karuturi MS, Reinbolt RE, Speca JC, Muss HB. Patient-Reported Toxicities During Chemotherapy Regimens in Current Clinical Practice for Early Breast Cancer. Oncologist 2019;24:762-71. [PMID: 30552158 DOI: 10.1634/theoncologist.2018-0590] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 5.7] [Reference Citation Analysis]
209 Citrin DE, Prasanna PGS, Walker AJ, Freeman ML, Eke I, Barcellos-Hoff MH, Arankalayil MJ, Cohen EP, Wilkins RC, Ahmed MM, Anscher MS, Movsas B, Buchsbaum JC, Mendonca MS, Wynn TA, Coleman CN. Radiation-Induced Fibrosis: Mechanisms and Opportunities to Mitigate. Report of an NCI Workshop, September 19, 2016. Radiat Res 2017;188:1-20. [PMID: 28489488 DOI: 10.1667/RR14784.1] [Cited by in Crossref: 41] [Cited by in F6Publishing: 20] [Article Influence: 10.3] [Reference Citation Analysis]
210 Patel JD, Briones M, Mandhani M, Jones S, Suthar D, Gray R, Pettus J, McCracken C, Thomas A, Petit CJ. Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis. J Am Coll Cardiol 2021;77:2807-18. [PMID: 34082911 DOI: 10.1016/j.jacc.2021.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
211 Brousell SC, Fantony JJ, Van Noord MG, Harrison MR, Inman BA. Vinflunine for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract: an evidence-based review of safety, efficacy, and place in therapy. Core Evid 2018;13:1-12. [PMID: 29416444 DOI: 10.2147/CE.S118670] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
212 Flannery MA, Culakova E, Canin BE, Peppone L, Ramsdale E, Mohile SG. Understanding Treatment Tolerability in Older Adults With Cancer. J Clin Oncol 2021;39:2150-63. [PMID: 34043433 DOI: 10.1200/JCO.21.00195] [Reference Citation Analysis]
213 Fiteni F, Ray IL, Ousmen A, Isambert N, Anota A, Bonnetain F. Health-related quality of life as an endpoint in oncology phase I trials: a systematic review. BMC Cancer 2019;19:361. [PMID: 30991990 DOI: 10.1186/s12885-019-5579-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
214 Reeve BB, McFatrich M, Mack JW, Maurer SH, Jacobs SS, Freyer DR, Withycombe JS, Baker JN, Castellino SM, Lin L, Lucas NR, Hinds PS. Validity and Reliability of the Pediatric Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events. J Natl Cancer Inst 2020;112:1143-52. [PMID: 31999349 DOI: 10.1093/jnci/djaa016] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
215 Cheng Z, Nakatsugawa M, Hu C, Robertson SP, Hui X, Moore JA, Bowers MR, Kiess AP, Page BR, Burns L, Muse M, Choflet A, Sakaue K, Sugiyama S, Utsunomiya K, Wong JW, McNutt TR, Quon H. Evaluation of classification and regression tree (CART) model in weight loss prediction following head and neck cancer radiation therapy. Adv Radiat Oncol 2018;3:346-55. [PMID: 30197940 DOI: 10.1016/j.adro.2017.11.006] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
216 Yang D, Yang J, Hu X, Chen J, Gao L, Cheng H, Tang G, Luo Y, Zhang W, Wang J. Aplastic Anemia Preconditioned with Fludarabine, Cyclophosphamide, and Anti-Thymocyte Globulin. Ann Transplant 2019;24:461-71. [PMID: 31395850 DOI: 10.12659/AOT.915696] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
217 Seruga B, Templeton AJ, Badillo FEV, Ocana A, Amir E, Tannock IF. Under-reporting of harm in clinical trials. The Lancet Oncology 2016;17:e209-19. [DOI: 10.1016/s1470-2045(16)00152-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
218 Jethwa KR, Park SS, Gonuguntla K, Wick SM, Vallow LA, Deufel CL, Whitaker TJ, Furutani KM, Ruddy KJ, Corbin KS, Hieken TJ, Mutter RW. Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen. Int J Radiat Oncol Biol Phys 2019;104:75-82. [PMID: 30583041 DOI: 10.1016/j.ijrobp.2018.12.025] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 4.3] [Reference Citation Analysis]
219 Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E; National Cancer Institute PRO-CTCAE Study Group. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncol 2015;1:1051-9. [PMID: 26270597 DOI: 10.1001/jamaoncol.2015.2639] [Cited by in Crossref: 309] [Cited by in F6Publishing: 220] [Article Influence: 61.8] [Reference Citation Analysis]
220 Hertz DL, Arwood MJ, Stocco G, Singh S, Karnes JH, Ramsey LB. Planning and Conducting a Pharmacogenetics Association Study. Clin Pharmacol Ther 2021;110:688-701. [PMID: 33880756 DOI: 10.1002/cpt.2270] [Reference Citation Analysis]
221 Jatoi A, Qin R, Satele D, Dakhil S, Kumar P, Johnson DB, Thomas SP, Stella PJ, Castillo J, Li M, Fernandez-zapico M. “Enjoy glass of wine before eating:” a randomized trial to test the orexigenic effects of this advice in advanced cancer patients. Support Care Cancer 2016;24:3739-46. [DOI: 10.1007/s00520-016-3190-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
222 Pearce A, Haas M, Viney R, Pearson SA, Haywood P, Brown C, Ward R. Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study. PLoS One 2017;12:e0184360. [PMID: 29016607 DOI: 10.1371/journal.pone.0184360] [Cited by in Crossref: 116] [Cited by in F6Publishing: 72] [Article Influence: 29.0] [Reference Citation Analysis]
223 Nielsen LK, Stege C, Lissenberg-Witte B, van der Holt B, Mellqvist UH, Salomo M, Bos G, Levin MD, Visser-Wisselaar H, Hansson M, van der Velden A, Deenik W, Coenen J, Hinge M, Klein S, Tanis B, Szatkowski D, Brouwer R, Westerman M, Leys R, Sinnige H, Haukås E, van der Hem K, Durian M, Gimsing P, van de Donk N, Sonneveld P, Waage A, Abildgaard N, Zweegman S. Health-related quality of life in transplant ineligible newly diagnosed multiple myeloma patients treated with either thalidomide or lenalidomide-based regimen until progression: a prospective, open-label, multicenter, randomized, phase 3 study. Haematologica 2020;105:1650-9. [PMID: 31515355 DOI: 10.3324/haematol.2019.222299] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
224 Yang SS, Chen L, Liu Y, Lu HJ, Huang BJ, Lin AH, Sun Y, Ma J, Xie FY, Mao YP. Validity and reliability of the simplified Chinese patient-reported outcomes version of the common terminology criteria for adverse events. BMC Cancer 2021;21:860. [PMID: 34315423 DOI: 10.1186/s12885-021-08610-0] [Reference Citation Analysis]
225 Lacouture ME, Dréno B, Ascierto PA, Dummer R, Basset-Seguin N, Fife K, Ernst S, Licitra L, Neves RI, Peris K, Puig S, Sokolof J, Sekulic A, Hauschild A, Kunstfeld R. Characterization and Management of Hedgehog Pathway Inhibitor-Related Adverse Events in Patients With Advanced Basal Cell Carcinoma. Oncologist 2016;21:1218-29. [PMID: 27511905 DOI: 10.1634/theoncologist.2016-0186] [Cited by in Crossref: 67] [Cited by in F6Publishing: 47] [Article Influence: 13.4] [Reference Citation Analysis]
226 Withycombe JS, McFatrich M, Pinheiro L, Hinds PS, Keller FG, Baker JN, Mack JW, Sung L, Waldron MK, Reeve BB. The association of age, literacy, and race on completing patient-reported outcome measures in pediatric oncology. Qual Life Res 2019;28:1793-801. [PMID: 30656534 DOI: 10.1007/s11136-019-02109-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
227 Hindiskere S, Errani C, Doddarangappa S, Ramaswamy V, Rai M, Chinder PS. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone? Clin Orthop Relat Res 2020;478:2522-33. [PMID: 32401001 DOI: 10.1097/CORR.0000000000001285] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
228 Smith GL, Ganz PA, Bekelman JE, Chmura SJ, Dignam JJ, Efstathiou JA, Jagsi R, Johnstone PA, Steinberg ML, Williams SB, Yu JB, Zietman AL, Weichselbaum RR, Tina Shih YC. Promoting the Appropriate Use of Advanced Radiation Technologies in Oncology: Summary of a National Cancer Policy Forum Workshop. Int J Radiat Oncol Biol Phys 2017;97:450-61. [PMID: 28011046 DOI: 10.1016/j.ijrobp.2016.10.042] [Cited by in Crossref: 26] [Cited by in F6Publishing: 14] [Article Influence: 5.2] [Reference Citation Analysis]
229 Ooki A, Morita S, Tsuji A, Iwamoto S, Hara H, Tanioka H, Satake H, Kataoka M, Kotaka M, Kagawa Y, Nakamura M, Shingai T, Ishikawa M, Miyake Y, Suto T, Hashiguchi Y, Yabuno T, Ando M, Sakamoto J, Yamaguchi K. Disagreement between patient- and physician-reported outcomes on symptomatic adverse events as poor prognosis in patients treated with first-line cetuximab plus chemotherapy for unresectable metastatic colorectal cancer: Results of Phase II QUACK trial. Cancer Med 2020;9:9419-30. [PMID: 33222406 DOI: 10.1002/cam4.3564] [Reference Citation Analysis]
230 Taarnhøj GA, Lindberg H, Johansen C, Pappot H. Patient-reported outcomes item selection for bladder cancer patients in chemo- or immunotherapy. J Patient Rep Outcomes 2019;3:56. [PMID: 31440865 DOI: 10.1186/s41687-019-0141-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
231 Kirsch M, Mitchell SA, Dobbels F, Stussi G, Basch E, Halter JP, De Geest S. Linguistic and content validation of a German-language PRO-CTCAE-based patient-reported outcomes instrument to evaluate the late effect symptom experience after allogeneic hematopoietic stem cell transplantation. Eur J Oncol Nurs 2015;19:66-74. [PMID: 25190633 DOI: 10.1016/j.ejon.2014.07.007] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.9] [Reference Citation Analysis]
232 Nyrop KA, Deal AM, Choi SK, Wagoner CW, Lee JT, Wood WA, Anders C, Carey LA, Dees EC, Jolly TA, Reeder-Hayes KE, Muss HB. Measuring and understanding adherence in a home-based exercise intervention during chemotherapy for early breast cancer. Breast Cancer Res Treat. 2018;168:43-55. [PMID: 29124455 DOI: 10.1007/s10549-017-4565-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
233 Stover A, Irwin DE, Chen RC, Chera BS, Mayer DK, Muss HB, Rosenstein DL, Shea TC, Wood WA, Lyons JC, Reeve BB. Integrating Patient-Reported Outcome Measures into Routine Cancer Care: Cancer Patients' and Clinicians' Perceptions of Acceptability and Value. EGEMS (Wash DC) 2015;3:1169. [PMID: 26557724 DOI: 10.13063/2327-9214.1169] [Cited by in Crossref: 14] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
234 Cho HJ, Seo SK, Baek DW, Park SW, Lee YJ, Sohn SK, Lee HS, Lee WS, Lee JH, Kim SH, Moon JH. Chemotherapy adherence is a favorable prognostic factor for elderly patients with multiple myeloma who are treated with a frontline bortezomib-containing regimen. Yeungnam Univ J Med 2018;35:76-83. [PMID: 31620574 DOI: 10.12701/yujm.2018.35.1.76] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
235 Atkinson TM, Hay JL, Dueck AC, Mitchell SA, Mendoza TR, Rogak LJ, Minasian LM, Basch E. What Do "None," "Mild," "Moderate," "Severe," and "Very Severe" Mean to Patients With Cancer? Content Validity of PRO-CTCAE™ Response Scales. J Pain Symptom Manage 2018;55:e3-6. [PMID: 29129739 DOI: 10.1016/j.jpainsymman.2017.10.024] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
236 Hall ET, Singhal S, Dickerson J, Gabster B, Wong HN, Aslakson RA, Schapira L; AAHPM Research Committee Writing Group. Patient-Reported Outcomes for Cancer Patients Receiving Checkpoint Inhibitors: Opportunities for Palliative Care-A Systematic Review. J Pain Symptom Manage 2019;58:137-156.e1. [PMID: 30905677 DOI: 10.1016/j.jpainsymman.2019.03.015] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 10.0] [Reference Citation Analysis]
237 Basch E, Becker C, Rogak LJ, Schrag D, Reeve BB, Spears P, Smith ML, Gounder MM, Mahoney MR, Schwartz GK, Bennett AV, Mendoza TR, Cleeland CS, Sloan JA, Bruner DW, Schwab G, Atkinson TM, Thanarajasingam G, Bertagnolli MM, Dueck AC. Composite grading algorithm for the National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Clin Trials 2021;18:104-14. [PMID: 33258687 DOI: 10.1177/1740774520975120] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
238 Kluetz PG, O'Connor DJ, Soltys K. Incorporating the patient experience into regulatory decision making in the USA, Europe, and Canada. Lancet Oncol 2018;19:e267-74. [PMID: 29726391 DOI: 10.1016/S1470-2045(18)30097-4] [Cited by in Crossref: 67] [Cited by in F6Publishing: 23] [Article Influence: 33.5] [Reference Citation Analysis]
239 Peuvrel L, Cassecuel J, Bernier C, Quéreux G, Saint-Jean M, Le Moigne M, Frénard C, Khammari A, Dréno B; Supported by GESTIM Nantes group of cutaneous adverse events induced by cancer treatments. TOXICAN: a guide for grading dermatological adverse events of cancer treatments. Support Care Cancer 2018;26:2871-7. [PMID: 29532244 DOI: 10.1007/s00520-018-4153-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
240 Mccrary JM, Goldstein D, Trinh T, Timmins HC, Li T, Friedlander M, Bosco A, Harrison M, Maier N, O'neill S, Park SB. Optimizing Clinical Screening for Chemotherapy-Induced Peripheral Neuropathy. Journal of Pain and Symptom Management 2019;58:1023-32. [DOI: 10.1016/j.jpainsymman.2019.07.021] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
241 Qiu RJ, Li M, Hu JY, Chen J, Shang HC. Methods for development of a core outcome set for clinical trials integrating traditional Chinese medicine and Western medicine. J Integr Med 2021:S2095-4964(21)00061-3. [PMID: 34384714 DOI: 10.1016/j.joim.2021.07.001] [Reference Citation Analysis]
242 Qu HL, Guo DD, Xu T, Li Z, Yin J, Tian XP, Kong DQ, Zhu XM, Miao LY, Wu DP, Tang XW. [CYP2C19 genetic polymorphism and monitoring voriconazole plasma concentrations in the treatment and prevention of invasive fungal disease for hematological patients]. Zhonghua Xue Ye Xue Za Zhi 2018;39:202-6. [PMID: 29562464 DOI: 10.3760/cma.j.issn.0253-2727.2018.03.006] [Reference Citation Analysis]
243 King-Kallimanis BL, Howie LJ, Roydhouse JK, Singh H, Theoret MR, Blumenthal GM, Kluetz PG. Patient reported outcomes in anti-PD-1/PD-L1 inhibitor immunotherapy registration trials: FDA analysis of data submitted and future directions. Clin Trials 2019;16:322-6. [PMID: 30880446 DOI: 10.1177/1740774519836991] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 8.0] [Reference Citation Analysis]
244 Holländer-Mieritz C, Johansen J, Johansen C, Vogelius IR, Kristensen CA, Pappot H. Comparing the patients' subjective experiences of acute side effects during radiotherapy for head and neck cancer with four different patient-reported outcomes questionnaires. Acta Oncol 2019;58:603-9. [PMID: 30698098 DOI: 10.1080/0284186X.2018.1563713] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 3.5] [Reference Citation Analysis]
245 King-Kallimanis BL, Kanapuru B, Blumenthal GM, Theoret MR, Kluetz PG. Age-related differences in patient-reported outcomes in patients with advanced lung cancer receiving anti-PD-1/PD-L1 therapy. Semin Oncol 2018;45:201-9. [PMID: 30482633 DOI: 10.1053/j.seminoncol.2018.06.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
246 Ganz PA. Improving the Quality and Value of Cancer Care: A Work in Progress-The 2016 Joseph V. Simone Award and Lecture. J Oncol Pract 2016;12:876-9. [PMID: 27531382 DOI: 10.1200/JOP.2016.015339] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
247 Bæksted C, Nissen A, Pappot H, Bidstrup PE, Mitchell SA, Basch E, Dalton SO, Johansen C. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). J Pain Symptom Manage 2016;52:292-7. [PMID: 27090851 DOI: 10.1016/j.jpainsymman.2016.02.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
248 Lee YI, Park Y, Park SJ, Kim TI, Kim WH, Cheon JH. Comparison of Long-Term Outcomes of Infliximab versus Adalimumab Treatment in Biologic-Naïve Patients with Ulcerative Colitis. Gut Liver 2021;15:232-42. [PMID: 32616683 DOI: 10.5009/gnl19433] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
249 Cameron D, Morden JP, Canney P, Velikova G, Coleman R, Bartlett J, Agrawal R, Banerji J, Bertelli G, Bloomfield D, Brunt AM, Earl H, Ellis P, Gaunt C, Gillman A, Hearfield N, Laing R, Murray N, Couper N, Stein RC, Verrill M, Wardley A, Barrett-Lee P, Bliss JM; TACT2 Investigators. Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncol 2017;18:929-45. [PMID: 28600210 DOI: 10.1016/S1470-2045(17)30404-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 10] [Article Influence: 8.8] [Reference Citation Analysis]
250 Soh JY, Cha WC, Chang DK, Hwang JH, Kim K, Rha M, Kwon H. Development and Validation of a Multidisciplinary Mobile Care System for Patients With Advanced Gastrointestinal Cancer: Interventional Observation Study. JMIR Mhealth Uhealth 2018;6:e115. [PMID: 29735478 DOI: 10.2196/mhealth.9363] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 4.7] [Reference Citation Analysis]
251 Harder H, Shilling VM, May SF, Cella D, Schmid P, Fallowfield LJ. The development and initial evaluation of the Diarrhoea Management Diary (DMD) in patients with metastatic breast cancer. Breast Cancer Res Treat 2020;183:629-38. [PMID: 32720113 DOI: 10.1007/s10549-020-05798-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
252 Salz T, Ostroff JS, Nightingale CL, Atkinson TM, Davidson EC, Jinna SR, Kriplani A, Lesser GJ, Lynch KA, Mayer DK, Oeffinger KC, Patil S, Salner AL, Weaver KE. The Head and Neck Survivorship Tool (HN-STAR) Trial (WF-1805CD): A protocol for a cluster-randomized, hybrid effectiveness-implementation, pragmatic trial to improve the follow-up care of head and neck cancer survivors. Contemp Clin Trials 2021;107:106448. [PMID: 34023515 DOI: 10.1016/j.cct.2021.106448] [Reference Citation Analysis]
253 Friese CR, Harrison JM, Janz NK, Jagsi R, Morrow M, Li Y, Hamilton AS, Ward KC, Kurian AW, Katz SJ, Hofer TP. Treatment-associated toxicities reported by patients with early-stage invasive breast cancer. Cancer 2017;123:1925-34. [PMID: 28117882 DOI: 10.1002/cncr.30547] [Cited by in Crossref: 26] [Cited by in F6Publishing: 17] [Article Influence: 6.5] [Reference Citation Analysis]
254 Farley JH, Hines J, Lee NK, Brooks SE, Nair N, Brown CL, Doll KM, Sullivan EJ, Chapman-Davis E. Promoting health equity in the era of COVID-19. Gynecol Oncol 2020;158:25-31. [PMID: 32446719 DOI: 10.1016/j.ygyno.2020.05.023] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
255 Kawaguchi T, Azuma K, Sano M, Kim S, Kawahara Y, Sano Y, Shimodaira T, Ishibashi K, Miyaji T, Basch E, Yamaguchi T. The Japanese version of the National Cancer Institute's patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events. J Patient Rep Outcomes 2017;2:2. [PMID: 29757309 DOI: 10.1186/s41687-017-0022-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
256 Leahy AB, Feudtner C, Basch E. Symptom Monitoring in Pediatric Oncology Using Patient-Reported Outcomes: Why, How, and Where Next. Patient 2018;11:147-53. [PMID: 29071524 DOI: 10.1007/s40271-017-0279-z] [Cited by in Crossref: 29] [Cited by in F6Publishing: 14] [Article Influence: 9.7] [Reference Citation Analysis]
257 Oswald LB, Arredondo B, Kadono M, Martinez-Tyson D, Meade CD, Penedo F, Antoni MH, Soliman H, Costa RLB, Jim HSL. A mixed-methods study of cyclin-dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers. Cancer Med 2021;10:4823-31. [PMID: 34165265 DOI: 10.1002/cam4.4055] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
258 Atkinson TM, Stover AM, Storfer DF, Saracino RM, D'Agostino TA, Pergolizzi D, Matsoukas K, Li Y, Basch E. Patient-Reported Physical Function Measures in Cancer Clinical Trials. Epidemiol Rev 2017;39:59-70. [PMID: 28453627 DOI: 10.1093/epirev/mxx008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 4.7] [Reference Citation Analysis]
259 Iseli T, Berghmans T, Glatzer M, Rittmeyer A, Massard G, Durieux V, Buchsbaum T, Putora PM. Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy. ERJ Open Res 2020;6:00010-2020. [PMID: 32963993 DOI: 10.1183/23120541.00010-2020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
260 Moss HA, Havrilesky LJ. The use of patient-reported outcome tools in Gynecologic Oncology research, clinical practice, and value-based care. Gynecologic Oncology 2018;148:12-8. [DOI: 10.1016/j.ygyno.2017.11.011] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
261 Wang TQ, Samuel JN, Brown MC, Vennettilli A, Solomon H, Eng L, Liang M, Gill G, Merali Z, Tian C, Cheng NYH, Campbell M, Patel D, Liu AX, Liu G, Howell D. Routine Surveillance of Chemotherapy Toxicities in Cancer Patients Using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Oncol Ther 2018;6:189-201. [PMID: 32700029 DOI: 10.1007/s40487-018-0065-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
262 Chen JB, Pan ZB, Du DM, Qian W, Ma YY, Mu F, Xu KC. Hydrogen gas therapy induced shrinkage of metastatic gallbladder cancer: A case report. World J Clin Cases 2019;7:2065-74. [PMID: 31423439 DOI: 10.12998/wjcc.v7.i15.2065] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
263 Taarnhøj GA, Johansen C, Lindberg H, Basch E, Dueck A, Pappot H. Patient reported symptoms associated with quality of life during chemo- or immunotherapy for bladder cancer patients with advanced disease. Cancer Med 2020;9:3078-87. [PMID: 32154663 DOI: 10.1002/cam4.2958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
264 Zorinas A, Janušauskas V, Davidavičius G, Šimakauskas R, Puodžiukaitė L, Zakarkaitė D, Bilkis V, Čypienė RJ, Samalavičius RS, Onorato EM, Aidietis A, Ručinskas K. Retrospective analysis of single-center early and midterm results of transapical catheter-based mitral paravalvular leak closure with a purpose-specific device. Postepy Kardiol Interwencyjnej 2018;14:167-75. [PMID: 30008769 DOI: 10.5114/aic.2018.76408] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
265 Samaan MA, Pavlidis P, Papa S, Powell N, Irving PM. Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. Nat Rev Gastroenterol Hepatol. 2018;15:222-234. [PMID: 29512649 DOI: 10.1038/nrgastro.2018.14] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 14.0] [Reference Citation Analysis]
266 Flannery M, Mohile SG, Dale W, Arora NK, Azar L, Breslau ES, Cohen HJ, Dotan E, Eldadah BA, Leach CR, Mitchell SA, Rowland JH, Hurria A. Interventions to improve the quality of life and survivorship of older adults with cancer: The funding landscape at NIH, ACS and PCORI. J Geriatr Oncol 2016;7:225-33. [PMID: 27197917 DOI: 10.1016/j.jgo.2016.02.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
267 Bennett AV, Dueck AC, Mitchell SA, Mendoza TR, Reeve BB, Atkinson TM, Castro KM, Denicoff A, Rogak LJ, Harness JK, Bearden JD, Bryant D, Siegel RD, Schrag D, Basch E; National Cancer Institute PRO-CTCAE Study Group. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Health Qual Life Outcomes 2016;14:24. [PMID: 26892667 DOI: 10.1186/s12955-016-0426-6] [Cited by in Crossref: 56] [Cited by in F6Publishing: 39] [Article Influence: 11.2] [Reference Citation Analysis]
268 Lee CT, Dong Y, Li T, Freedman S, Anaokar J, Galloway TJ, Hallman MA, Weiss SE, Hayes SB, Price RA, Ma CMC, Meyer JE. Local Control and Toxicity of External Beam Reirradiation With a Pulsed Low-dose-rate Technique. Int J Radiat Oncol Biol Phys 2018;100:959-64. [PMID: 29485075 DOI: 10.1016/j.ijrobp.2017.12.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
269 Pusic AL, Temple LK, Carter J, Stabile CM, Assel MJ, Vickers AJ, Niehaus K, Ancker JS, McCready T, Stetson PD, Simon BA. A Randomized Controlled Trial Evaluating Electronic Outpatient Symptom Monitoring After Ambulatory Cancer Surgery. Ann Surg 2021;274:441-8. [PMID: 34132697 DOI: 10.1097/SLA.0000000000005005] [Reference Citation Analysis]
270 Hébert V, Vermeulin T, Tanguy L, Tedbirt B, Mignard C, Bénichou J, Joly P. Comparison of real costs in the French healthcare system in newly diagnosed patients with pemphigus for first‐line treatment with rituximab vs. standard corticosteroid regimen: data from a national multicentre trial. Br J Dermatol 2020;183:121-7. [DOI: 10.1111/bjd.18563] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 9.0] [Reference Citation Analysis]